Newsroom.

(22 April 2025): Recce Pharmaceuticals (ASX:RCE) has received Human Research Ethics Approval (HREC) to enrol up to 20 additional patients with Diabetic Foot Infections in its Phase 2 trial of R327G.

(17 April 2025): Telix Pharmaceuticals (ASX:TLX) has announced that preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma support the patient benefit seen in the IPAX-1 study.

(17 April 2025): Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced the US FDA has granted PTX-100 a Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of Cutaneous T Cell Lymphoma.

(15 April 2025): Cell therapy immuno-oncology company Carina Biotech has reported a successful $5 million capital raise from existing and new shareholders.

(15 April 2025): Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has passed its final in vivo preclinical safety study before regulatory submission for the upcoming HERACLES clinical trial.

(15 April 2025): Neuren Pharmaceuticals (ASX:NEU) has announced that the primary endpoints for its planned single Phase 3 pivotal clinical trial of NNZ-2591 in Phelan-McDermid syndrome have been confirmed at a Type C Meeting with the US FDA.

(10 April 2025): Researchers at the Walter and Eliza Hall Institute of Medical Research have shown that a new drug compound can prevent long COVID symptoms in mice.

(10 April 2025): Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the appointment of Melanie Farris to the board as an independent non-executive director.

(10 April 2025): Recce Pharmaceuticals (ASX:RCE) has announced a significant capital raise to support Phase 3 topical clinical trials in Indonesia and Australia.

(10 April 2025): Opthea (ASX:OPT) has updated investors following the recent termination of its COAST (Combination of OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab) Phase 3 clinical trials.

(8 April 2025): The Baker Institute says the installation of next-generation proteomics and multi-omics technology this month will provide insights into cardiovascular biology, cell signalling and human health, supporting its researchers to accelerate the understanding of human cardiovascular health and disease.

(3 April 2025): Percheron Therapeutics (ASX:PER) has updated shareholders on its actions following the disappointing result in the Phase 2b trial of its avicursen in non-ambulant boys with Duchenne muscular dystrophy.

(1 April 2025): Opthea (ASX:OPT) has announced it will discontinue clinical trials involving its sozinibercept in combination with other therapies for treating wet age-related macular degeneration.

(27 March 2025): Amplia Therapeutics (ASX:ATX) has reported updated data from its ongoing Phase 2a ACCENT clinical trial investigating its FAK inhibitor narmafotinib in combination with standard-of-care chemotherapy in treating advanced pancreatic cancer.

(27 March 2025): Neuren Pharmaceuticals (ASX:NEU) has initiated the development of NNZ-2591 to treat hypoxic-ischemic encephalopathy.

(25 March 2025): Opthea (ASX:OPT) has reported negative outcomes from its pivotal Phase 3 clinical trial involving the combination of its sozinibercept with Bayer's EYLEA (aflibercept) for treating wet age-related macular degeneration.

(25 March 2025): Noxopharm (ASX:NOX) has announced an expanded work program for 2025 with its strategic partner, Melbourne’s Hudson Institute of Medical Research.

(25 March 2025): Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the US Patent and Trademark Office has allowed the issuance of a patent application covering the company's CHM CDH17 chimeric antigen receptor technology.

(20 March 2025): Since 2000, when it started in a makeshift basement laboratory, QBiotics has spent 25 years focused on discovering and developing novel cell signalling small molecules for challenging medical conditions.

(20 March 2025): Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced that the US FDA has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

(20 March 2025): Late-stage immunotherapy company Immutep (ASX:IMM) has announced an upcoming poster presentation for the pivotal TACTI-004 Phase 3 trial.

(18 March 2025): Race Oncology (ASX:RAC) has announced that Bellberry has approved a phase one clinical trial of RC220 bisantrene alone and combined with doxorubicin in patients with solid tumours.

(18 March 2025): engagement with the US FDA on lifting the clinical hold on the company's investigational new drug application for NUZ-001.

(18 March 2025): Nyrada (ASX:NYR) has commenced recruitment for its phase one clinical trial of its lead drug candidate NYR-BI03.

(18 March 2025): OncoSil Medical (ASX:OSL) has announced the appointment of Shelley Steyn as chief financial officer, effective 5 May.

(13 March 2025): Australian biotechnology company Noxopharm (ASX:NOX) has engaged Doherty Clinical Trials to conduct its upcoming phase 1 HERACLES trial.

(13 March 2025): Proteomics International Laboratories (ASX:PIQ) has officially launched its first-in-class predictive test for diabetic kidney disease, PromarkerD, in Australia.

(13 March 2025): Telix Pharmaceuticals (ASX:TLX) has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine.

(11 March 2025): Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that Dr James Campbell will succeed Steven Engle as its chair.

(11 March 2025): PolyNovo (ASX:PNV) has announced that its chief executive officer, Swami Raote, will officially leave the company in June but will step down immediately.

(6 March 2025): A new report by Telix says the tens of thousands of Australians could miss out on a new era of cancer treatment without action from the government to secure the viability of the nuclear medicine sector, including enforcing regulatory standards.

(6 March 2025): Clinical-stage biotechnology company Vaxxas has announced the publication of data supporting the potential use of its high-density microarray patch technology to deliver nucleic acid-based vaccines in collaboration with The University of Queensland and Technovalia.

(6 March 2025): "Through his leadership, BioMelbourne Network has solidified its position within the Victorian health technologies sector, delivering positive outcomes for members and stakeholders and contributing to the advancement of life sciences," said the organisation.

(4 March 2025): Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Darren Keamy as its chief financial officer and company secretary starting today.

(4 March 2025): Avecho Biotechnology (ASX:AVE) and Sandoz have signed an exclusive ten-year development and licensing agreement for the commercial rights to the Australian company's phase 3 cannabidiol capsule for insomnia in Australia.

(4 March 2025): CSL Seqirus has signed an agreement Esperion Therapeutics for the exclusive license and distribution agreement to commercialise NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Australia and New Zealand.

(27 February 2025): Clinical-stage regenerative medicine company Cambium Bio (ASX:CMB) has announced that the US FDA has approved the protocol for the registration-enabling Phase 3 clinical trials of Elate Ocular for the treatment of moderate to severe dry eye disease.

(27 February 2025): Neuren Pharmaceuticals (ASX:NEU) has updated investors on the 2024 earnings announcement and conference call of its partner, Acadia Pharmaceuticals.

(27 February 2025): Arovella Therapeutics (ASX:ALA) has announced that it has received firm commitments from institutional and sophisticated investors to raise approximately $15 million under a new placement.

(27 February 2025): Telix Pharmaceuticals (ASX:TLX) has announced that the US FDA has accepted its Biologics License Application for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix, 89ZrDFO-girentuximab).

(25 February 2025): A new whitepaper from On Q Recruitment explores the key findings of its 2024 Salary & Job Market Report, highlighting how salary trends shape Australia’s life sciences industry.

(25 February 2025): Neuren Pharmaceuticals (ASX:NEU) has received a Rare Paediatric Disease Designation from the US FDA for NNZ-2591 in Pitt-Hopkins syndrome and Angelman syndrome.

(25 February 2025): Regenerative medicine company Orthocell (ASX:OCC) has submitted an application to the Thai Food and Drug Administration for its leading nerve repair product, Remplir.

(20 February 2025): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced that the US FDA has granted fast-track designation for 67Cu-SAR-bisPSMA for the treatment of adult patients with a form of prostate cancer.

(20 February 2025): The US FDA has granted fast-track designation for Neuren's NNZ-2591 for the treatment of Pitt Hopkins syndrome.

(20 February 2025): Vaxxas has completed enrollment for its Phase 1 clinical trial of a vaccine against an avian influenza A (H7N9) virus with pandemic potential, delivered by the company’s proprietary high-density microarray patch.

(18 February 2025): Clinical-stage drug development company Syntara (ASX:SNT) has announced new findings from a subgroup analysis of 14 patients from the placebo-controlled SOLARIA2 trial.

(11 February 2025): PYC Therapeutics (ASX:PYC) has announced that it has received all required regulatory approvals to commence human clinical trials of PYC-003.

(11 February 2025): Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly to research and develop innovative cancer treatments.

(11 February 2025): CEO and managing director Dr Paul McKenzie said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans."

(6 February 2025): Clinical-stage company Vaxxas has announced the appointments of three respected vaccine experts as advisors to its product development and strategy team as it advances its novel high-density microarray patch (HD-MAP) vaccine technology towards later-stage clinical trials and commercialisation.

(6 February 2025): AdAlta (ASX:1AD) has announced it will accelerate its 'East to West' cellular immunotherapy growth strategy by executing two non-binding term sheets to in-license clinical-stage CAR-T products, bringing total products in advanced due diligence to three.

(4 February 2025): AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, has successfully completed an oversubscribed US$112 million Series C financing.

(4 February 2025): Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has successfully passed a set of important preclinical safety tests ahead of the upcoming HERACLES clinical trial.

(4 February 2025): Argenica Therapeutics (ASX:AGN) has announced results from a more extensive preclinical study assessing the efficacy of ARG-007 in a rat model of moderate traumatic brain injury.

(28 January  2025): “I realised we had something special when our lead scientist on this programme came into my office and showed me some data related to the screening they'd been doing," said Dr Andrew Nash, CSL’s chief scientific officer.

(28 January 2025): Telix Pharmaceuticals (ASX:TLX) has completed the acquisition of RLS (RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network that distributes PET, SPECT, and therapeutic radiopharmaceuticals.

(23 January 2025): Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial.

(21 Jan 2025):  Global Contract Development and Manufacturing Organisations BioCina and NovaCina have announced a strategic merger to create a new biopharmaceutical and small molecule contract manufacturing brand.

(21 January 2025): Vaxxas CEO David Hoey said, “We're honoured to have our world-leading microarray patch technology chosen to be part of this important BARDA-led public health initiative to accelerate new vaccine technologies."

(21 January 2025): Neuren has announced that its partner Acadia has submitted a Marketing Authorisation Application to the EMAfor DAYBUE (trofinetide) for the treatment of Rett syndrome.

(20 December 2024): Race Oncology (ASX:RAC) has announced the appointment of experienced biotechnology executive Dr Megan Baldwin to its board as an independent non-executive director.

(17 December 2024): Led by BioMelbourne Network, the new initiative brings together expertise from peak industry bodies and companies to create a voice and advocate on behalf of Victorian medtech manufacturers across the key issues impacting the sector.

(17 December 2024): Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II in humans.

(12 December 2024): Clinical-stage biotechnology company FivepHusion has announced a commercial transaction with the University of Wollongong for an exclusive option over its ResectAssist Drug Delivery Platform.

(12 December 2024): An immunotherapy that targets out-of-control viral infections has saved the lives of dozens of critically ill immunocompromised Australians who received the treatment on compassionate grounds.

(12 December 2024): Immutep (ASX:IMM) has announced positive clinical results from Cohort B of the TACTI-003 (KEYNOTEC34) Phase 2b trial.

(12 December 2024): Neuren Pharmaceuticals (ASX: NEU) has announced that the sale of the Rare Pediatric Disease Priority Review Voucher by its partner Acadia Pharmaceuticals has been completed.

(10 December 2024): Paradigm Biopharmaceuticals (ASX:PAR) has announced that it has received firm commitments for a capital raising totalling $16 million through a placement of fully paid ordinary shares to sophisticated and institutional investors.

(10 December 2024): Clinical-stage biotechnology company FivepHusion has announced Human Regulatory Ethics Committee approval for the next clinical trial of Deflexifol to treat solid tumours.

(10 December 2024): Recce Pharmaceuticals (ASX:RCE) has received approval from the Indonesian Drug and Food Regulatory Authority to initiate its registrational Phase 3 clinical trial, which will assess RECCE 327 as a topical gel for treating diabetic foot infections.

(5 December 2024): Race Oncology (ASX:RAC) has announced the submission of the ethics and regulatory package to Bellberry Human Research Ethics Committee for approval of a Phase 1 clinical trial of RC220.

(4 December 2024): Regenerative medicine company Orthocell (ASX:OCC) has announced the successful completion of its Remplir 510(k) nerve repair study.

(26 November 2024): GE HealthCare and Peter MacCallum Cancer Centre have announced a partnership under which the Melbourne-based facility will evaluate a new positron emission tomography and computed tomography technology

(26 November 2024): Professor David Thomas said, “We are on the cusp of a new era in cancer care. It’s imperative to integrate this approach as mainstream care for all Australians.”

(26 November 2024): CEO and managing director Brent Barnes said, “With the growing sales momentum of APAS, we believe now is the ideal time to streamline and simplify communications with our customers and shareholders under the unified identity of Clever Culture Systems.”

(21 November 2024): Race Oncology (ASX:RAC) says it has completed an FTO-targeted drug discovery program at Monash University’s Fragment Platform.

(21 November 2024): BioMelbourne Network is launching a one-year project to develop a central portal containing a workforce resource suite, thanks to the Victorian Government's support.

(19 November 2024): Australian company AdAlta (ASX:1AD) has announced the appointment of two new directors, including experienced industry executives Michelle Burke and Iain Ross.

(19 November 2024): Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, NUZ-001.

(14 November 2024): Amplia Therapeutics (ASX:ATX) has announced that it has entered into a research collaboration with Korean preclinical drug screening company Next&Bio.

(14 November 2024): Clinical-stage company Immutep (ASX:IMM) has announced positive data from the investigator-initiated INSIGHT-003 Phase 1 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.

(7 November 2024): Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has entered into a definitive asset purchase agreement to sell the Rare Pediatric Disease Priority Review Voucher for US$150 million.

(5 November 2024): Imugene (ASX:IMU) has announced that a bile tract cancer patient in its Phase 1 MAST trial remains a complete response, now surpassing more than two years in remission. 

(5 November 2024): Optiscan Imaging (ASX:OIL) has signed an agreement with Monash University to help the company advance its project to develop the next-gen gastrointestinal (GI) flexible endomicroscope and Edge-AI-enabled technology.

(5 November 2024): Recce Pharmaceuticals (ASX:RCE) says it is nearing completion of its Phase 2 clinical trial of RECCE 327 Topical Gel (R327G) targeting Acute Bacterial Skin and Skin Structure Infections.

(31 October 2024): Amplia Therapeutics (ASX:ATX) is undertaking a placement, director placement and entitlement offer to raise up to $13 million, with interim data from the ACCENT trial supporting its continuation.

(29 October 2024): "Published preclinical results show the potential immunogenic advantages of this antigen candidate as the basis for an RSV vaccine to provide robust and durable protection,” said Vaxxas CEO David Hoey.

(29 October 2024): Actinogen Medical (ASX:ACW) has announced the appointment of Andrew Udell, a US-based executive, as its chief commercial officer, reporting to CEO Dr Steven Gourlay.

(24 October 2024): Kevin Richardson, CEO of Telix Precision Medicine, said, “Telix believes that the FDA approval of Pixclara will drive a step-change for brain cancer imaging in the US and bring it into line with a more advanced standard of care currently used in other markets."

(24 October 2024): AdAlta (ASX:1AD) has announced an addition to its AdCella leadership team, with Dr Kevin Lynch appointed as consultant chief medical officer.

(24 October 2024): Percheron Therapeutics (ASX:PER) will undertake a share purchase plan for eligible existing shareholders to allow them to participate in a recently announced institutional placement.

(22 October 2024): Cell therapy company Chimeric Therapeutics (ASX:CHM) says it has received commitments for a two-tranche placement to sophisticated and professional investors to raise $5 million before costs.

(17 October 2024): CEO James Bonnar said, "We are thrilled to have completed the GLP studies, which have confirmed a favourable safety profile for NYR-BI03, giving us confidence that it will transition well into human studies."

(15 October 2024): Respiri chairman Nicholas Smedley said, “The Board and I are pleased to welcome investors of this calibre onto our registry."

(15 October 2024): Immuron (ASX:IMC) has announced the continued strong sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.

(10 October 2024): The CEO and managing director of Australian company Amplia Therapeutics (ASX:ATX), Dr Chris Burns, and Professor Andrew Wilks have shared the Prime Minister’s Prize for Innovation for their role in the discovery of JAK enzymes and their co-invention of the JAK inhibitor momelotinib.

(10 October 2024): Telix has announced that the TGA has approved the use of Illuccix to select patients for PSMA-targeted radionuclide therapy.

(10 October 2024): Noxopharm (ASX:NOX) has contracted a specialist supplier to manufacture SOF-SKN for the upcoming HERACLES clinical trial.

(8 October 2024): Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that a patient with Acute Myelogenous Leukemia has recorded a complete response in its Phase 1b CHM CORE-NK and Vactosertib combination.

(3 October 2024): Nyrada (ASX:NYR) has announced positive results from a preclinical rat study evaluating the efficacy of its lead drug candidate, NYR-BI03, in coronary heart disease.

(3 October 2024): Life sciences financier Endpoints Capital has advanced pioneering Australian firm Vaxxas $9.7 million for its Research and Development Tax Incentive.

(1 October 2024): Percheron Therapeutics (ASX:PER) has announced the completion of a nine-month toxicology study in non-human primates for its lead program, avicursen.

(1 October 2024): PolyNovo chairman David Williams said, “After 14 years Bruce has selflessly decided to stand aside to make way for new blood and concentrate on his other Board roles. He will be missed but I am confident he will still be available for his sage advice."

(1 October 2024): Cell therapy company Mesoblast (ASX:MSB) has entered into a convertible note subscription agreement with its largest shareholder, Gregory George, to issue up to US$50 million convertible notes at its discretion.

(26 September 2024): Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced a partnership with US-based Achieve that aims to improve patient access to autologous cell therapies.

(26 September 2024): Argenica Therapeutics (ASX:AGN) has announced the completion of crucial safety studies that are required to be included in its IND application.

(24 September 2024): Telix Pharmaceuticals (ASX:TLX) has announced it will acquire America's only joint commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals.

(24 September 2024): Immutep (ASX:IMM) has announced it has received a €2,194,918 (~A$3,6) research and development tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme

(19 September 2024): Cochlear (ASX:COH) has announced that Sarah Thom will be its chief financial officer, effective 1 January 2025.

(19 September 2024): Invion (ASX:IVX) has announced that RMW Cho Group, the licensor of the Photosoft technology, has completed a Phase 2 prostate cancer trial using a sublingual formulation of INV043.

(17 September 2024): Immutep (ASX:IMM) has announced positive efficacy and safety results from the TACTI-003 Phase 2b trial evaluating its eftilagimod alpha in combination with MSD’s KEYTRUDA.

(17 September 2024): Monash University researchers have discovered a blood cell that, when introduced to a bone, muscle, or skin injury, has the potential to promote rapid healing.
 

(17 September 2024): PharmAust (ASX:PAA) says it has completed a pre-submission meeting with the European Medicines Agency and the Committee for Orphan Medicinal Products and has submitted a request for orphan designation for monepantel for the treatment of amyotrophic lateral sclerosis.

(12 September 2024): Vaxxas has initiated a multi-centre Phase 1 clinical trial of a vaccine against pre-pandemic avian influenza strain H7N9, using its high-density microarray patch.

(12 September 2024): CUREator, Australia's national biotech incubator managed by Brandon BioCatalyst, has announced that four companies will receive top-up funding across its Preclinical and Health Security streams.

(12 September 2024): Telix (ASX:TLX) has announced that the primary results from its Phase 3 ZIRCON trial have been published in The Lancet Oncology.

(12 September 2024): Thanks to a $10 million donation, Cabrini Health, in partnership with Monash University, is aiming to transform cancer care for Victorians.

(10 September 2024): Australian clinical-stage biopharmaceutical company ENA Respiratory has been awarded an additional US$3.18 million contract from the US Department of Defense.

(10 September 2024): Dimerix (ASX:DXB) has announced that the first patient has completed the ACTION3 Phase 3 clinical trial, including the initial follow-up period, and has chosen to enter the global open-label extension study.

(10 September 2024): Nyrada (ASX:NYR) has provided an update on the development of its brain injury program with investigative first-in-class neuroprotection treatment, NYR-BI03.

(10 September 2024): Biotron (ASX:BIT) has provided an update on the BIT225-012 Phase 2 clinical trial of its lead antiviral drug BIT225 for treating COVID-19.

(5 September 2024): CSL Limited (ASX:CSL) has announced the sale of its Wuhan Zhong Yuan Rui De Biologicals Products (Ruide) plasma collection and fractionation operations to Chengdu Rongsheng Pharmaceutical for USD$185 million in cash proceeds.

(5 September 2024): Opthea (ASX:OPT) has announced executive leadership changes in finance and commercial and senior hires for biometrics, clinical operations and market access.

(5 September 2024): Noxopharm (ASX:NOX) has announced progress on its Chroma technology platform, encouraging early drug leads with anticancer activity for glioblastoma and leukaemia.

(5 September 2024): Percheron Therapeutics (ASX:PER) says preclinical data for its lead program, avicursen (ATL1102), further validates its pharmacological activity as an anti-inflammatory agent.

(2 September 2024): Race Oncology (ASX:RAC) has announced that the first phase of the board renewal process, which commenced in 2023, is now complete with a newly appointed board.

(29 August 2024): Contract Research Organisation Novotech has been recognised as a Workplace Gender Equality Agency Employer of Choice for Gender Equality in 2024.

(29 August 2024): Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the first patient enrolled in the first-in-human trial of CHM CDH17 has been dosed.

(29 August 2024): Telix (ASX:TLX) has submitted a New Drug Application to the US FDA for TLX101-CDx, an investigational PET agent for the characterisation of progressive or recurrent glioma from treatment-related changes in both adult and pediatric patients.

(27 August 2024): Cancer researcher and clinician Professor Maher Gandhi has been appointed as the next chief executive officer of Australia’s Translational Research Institute.

(27 August 2024): Clinical-stage biotechnology company PharmAust (ASX:PAA) has provided a four-month progress update on the ongoing 12-month Open-Label Extension study in patients with Amyotrophic Lateral Sclerosis.

(20 August 2024): Moderna has welcomed the Albanese Government's National Science Statement and its prioritisation of support for advanced manufacturing, sovereign capability, and innovative sciences.

(22 August 2024): Researchers at the University of Queensland Translational Research Institute have discovered how bladder cancer suppresses the immune system’s natural killer cells.

(22 August 2024): Amplia Therapeutics (ASX:ATX) has announced that a fifth patient enrolled in its Phase 2a ACCENT clinical trial in pancreatic cancer has recorded a confirmed partial response, meaning a 30 per cent or greater decrease in the overall size of tumour lesions maintained over two months, and with no new tumour lesions.

(20 August 2024): Noxopharm (ASX:NOX) has announced its first-in-human trial for SOF-SKN, a novel investigative candidate for autoimmune diseases.

(20 August 2024): Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced the completion of Good Manufacturing Practice manufacturing to enable treatment of the first clinical participant in the CHM CDH17 CAR-T trial.

(20 August 2024): Brisbane-based company De Motu Cordis, which is developing products to enable more rapid epinephrine absorption, has "enthusiastically" welcomed the US FDA's approval ARS Pharma's Neffy.

(15 August 2024): Noxopharm (ASX:NOX) has announced new data regarding its CRO-67 preclinical drug for pancreatic cancer.

(15 August 2024): Immutep (ASX:IMM) has announced that the first participant has been successfully dosed in the first-in human Phase 1 trial of IMP761.

(15 August 2024): A WEHI study could help solve a long-standing mystery into why a key immune organ in our bodies shrinks and loses its function as we age.

(13 August 2024): Chimeric Therapeutics (ASX:CHM) has announced a collaboration with Melbourne-based Cell Therapies to explore the potential of manufacturing its investigative CAR-T candidates.

(13 August 2024): CSL CEO and managing director Dr Paul McKenzie said, “I am pleased to report a strong result for the 2024 financial year led by CSL Behring."

(13 August 2024): Pfizer has released a new report recommending that the Government develop a vision for the Australian life sciences sector.

(8 August 2024): Researchers at the Brisbane QIMR Berghofer Medical Research Institute have developed immune cells that could improve glioblastoma survival by fighting the deadly brain cancer and preventing its recurrence. 

(8 August 2024): "We are thrilled to reach this important milestone in our investment to support the development and delivery of new antimicrobials at our Melbourne site, and to be investing in Australia’s advanced manufacturing capabilities,” said Anne Harris, the managing director of Pfizer Australia and New Zealand.

(6 August 2024): A new facility at The University of Queensland is set to provide Australian researchers with cancer vaccines tailored to individual patients.   

(1 August 2024): Scientists at the Australian National University are collaborating with the community to unlock the full potential of ribonucleic acid.

(1 August 2024): Melbourne-based pharmaceutical manufacturer IDT has announced a significant increase in quarterly revenue, reaching its highest level since its strategy update in late 2022.

(1 August 2024): Medical imaging technology company Imagion Biosystems (ASX:IBX) has announced changes to its board of directors.

(30 July 2024): Race Oncology (ASX:RAC) has announced that the investigator-sponsored Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine in relapsed or refractory acute myeloid leukaemia patients has been successfully concluded having achieved its primary endpoint for efficacy.

(30 July 2024):  Monash University has welcomed Health Minister Mark Butler's $19 million investment in six mRNA research projects via the Medical Research Future Fund.

(30 July 2024): Cochlear (ASX:COH) has announced that Caroline Clarke has been appointed a non-executive director to its board.

(25 July 2024):  Telix (ASX:TLX) is commercialising its therapeutic and diagnostic radiopharmaceuticals. Its share price has more than doubled in 2024, and the company now has a market capitalisation of almost $6.4 billion.

(25 July 2024): Regenerative medicine company Orthocell (ASX:OCC) has announced seven regulatory submissions are in progress or planned for its medical device platform products.

(23 July 2024): Australian cell therapy company Chimeric Therapeutics has announced that the first patients have been enrolled in the new clinical trial of its CHM CDH17 in patients with different forms of cancer.

(23 July 2024): Noxopharm (ASX:NOX) says a range of companies are evaluating its Sofra platform after signing several Material Transfer Agreements.

(18 July 2024):  Burnet senior research officer Dr Liriye Kurtovic has been awarded a Moderna Global Fellowship to support her research into developing a new malaria vaccine.

(18 July 2024): Queensland company De Motu Cordis has announced plans for the next stage of developing its investigative drug-device combination for anaphylaxis.

(18 July 2024): Australian company Alterity Therapeutics has announced positive interim data from the Phase 2 clinical trial of ATH434 in patients with multiple system atrophy.

(18 July 2024): The Western Australian Government has awarded over $2 million through its Future Health Research and Innovation Fund to set up a centre dedicated to developing RNA technology for cancer treatments.

(16 July 2024): A new treatment that could potentially reverse or stop the progression of traumatic brain injury will be developed at a new state-of-the-art biotechnology facility launched at La Trobe University

(16 July 2024): Rebecca Lee, the managing director of Merck Life Science Australia and New Zealand, confirmed that a breadth of services will be covered, such as fertility tests, in vitro fertilisation treatments, and hormonal treatments.

(16 July 2024): Immutep (ASX:IMM) has announced positive results from the second cohort of its Phase 2b trial involving its eftilagimod alfa in combination with MSD's KEYTRUDA (pembrolizumab).

(11 July 2024): Victorian Deputy Premier and Minister for Medical Research Ben Carroll has officially opened the newly built Medicines Manufacturing Innovation Centre in the Monash Technology Precinct.

(11 July 2024): Telix Pharmaceuticals (ASX:TLX) has welcomed proposed changes announced by the US Centers for Medicare and Medicaid Services.

(11 July 2024):  Regenerative medicine company Orthocell (ASX:OCC) has announced that Heath Canada has granted a Medical Device Licence for its product, Striate+, for guided bone regeneration in dental implant procedures.

(9 July 2024): Melbourne-based Alkira Bio, a novel drug discovery platform company, has announced an investment from US venture capital firm Curie.Bio.

(9 July 2024): Genetic Technologies (ASX:GTG) has introduced geneType’s suite of genetic risk assessment tests to Canada and New Zealand.

(9 July 2024): Regenerative medicine company Orthocell (ASX:OCC) has reported record revenue for the June quarter and year with growth in sales of its medical devices, Striate+ and Remplir.

(4 July 2024): Dimerix (ASX:DXB) has announced that recruitment of patients aged 12 to 17 has commenced for the ACTION3 Phase 3 clinical trial in patients with focal segmental glomerulosclerosis.

(4 July 2024): Amplia Therapeutics (ASX:ATX) has recruited 26 patients in the Phase 2a stage of its clinical trial investigating narmafotinib for treating advanced pancreatic cancer.

(2 July 2024): Professor Peter van Wijngaarden has been named the next director and CEO of The Florey Institute of Neuroscience and Mental Health.

(2 July 2024): The board of the Sydney-based Viral Vector Manufacturing Facility has appointed Stephen Thompson as its inaugural CEO.

(2 July 2024): Actinogen Medical (ASX:ACW) has announced that following yesterday's final trial patient visit in the UK, it expects top-line results for the XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder to be available in the first half of August.

(2 July 2024): BioMelbourne Network chair David Herd said, “Welcome to our new Directors who bring a depth of experience on boards and in leadership roles across our sector."

(27 June 2024): The CUREator+ Dementia and Cognitive Decline incubator program, a partnership between Brandon BioCatalyst, ANDHealth and Dementia Australia, has opened its first funding round.

(27 June 2024): Immutep (ASX:IMM) has announced topline results from the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial evaluating its eftilagimod alfa in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment of recurrent and metastatic head and neck squamous cell carcinoma.

(27 June 2024): Actinogen Medical (ASX:ACW) has announced the peer-reviewed publication of its phase 2a biomarker trial entitled 'Plasma pTau181 Predicts Clinical Progression In A Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem for Mild Alzheimer’s Disease' in the 100th edition of the Journal of Alzheimer’s Disease.

(25 June 2024): A number of promising compounds that block LAG-3, an immune checkpoint known to reduce the immune system’s response to fight cancer, have been identified under Immutep’s collaboration with the world-leading scientists at Cardiff University.

(25 June 2024): Unlike the injectable and nasal spray alternatives that require clinicians to monitor patients for two hours while side effects subside, the slow-release tablet form can be taken safely at home without medical supervision and with negligible side effects.

(25 June 2024): Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the dosing of the first patient in the intravenous infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial.

(20 June 2024): Biotron (ASX:BIT) has announced that preliminary data analyses from the BIT225-011 Phase 2 clinical trial of its lead antiviral drug BIT225 indicate that the primary objectives have been met.

(20 June 2024): The company is seeking applications from emerging biopharmaceutical and biotechnology start-ups in Australia and New Zealand for its Advance Biotech Grant Program.

(20 June 2024): QUT has joined the Artificial Heart Frontiers Program, a transdisciplinary consortium that aims to develop and commercialise a suite of revolutionary and life-changing implantable cardiac devices.

(18 June 2024): Health Minister Mark Butler has launched a new biotechnology company that will use an innovative technology to target cancers that are difficult to treat with existing medicines.

(18 June 2024): Race Oncology (ASX:RAC) has announced that the US FDA has extended Rare Paediatric Disease Designation to RC220 bisantrene to treat paediatric subtypes of acute myeloid leukemia.

(18 June 2024): Opthea (ASX:OPT) has announced the completion of the institutional component of the recently announced capital.

(11 June 2024): Australian company Opthea (ASX:OPT) has announced it is seeking to raise approximately $227.3 million to advance the late-stage development of OPT-302 (sozinibercept), a drug for progressive retinal diseases, including wet age-related macular degeneration.

(13 June 2024): Race Oncology (ASX:RAC) has reported the results of preclinical work performed under contract by US-based Labcorp of a mouse model involving bisantrene in combination with carfilzomib.

(13 June 2024): QBiotics Group has announced that its Phase 2a human clinical trial of tigilanol tiglate in Soft Tissue Sarcoma (STS) has completed recruitment. The final patient has received treatment and completed their 28-day follow-up.

(11 June 2024): Murdoch Children's Research Institute and Bangladesh-based Incepta Pharmaceuticals have announced a collaboration to bring life-saving innovation to the global healthcare landscape.

(11 June 2024): Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has updated investors on the PANCOSIL clinical trial.

(6 June 2024): Australia's largest cancer genomics initiative has achieved a significant milestone. Over 5,000 Australians diagnosed with hard-to-treat cancers with minimal treatment options have received referrals for free comprehensive genomic profiling.

(4 June 2024): WIPO Member States approve treaty addressing intellectual property (IP), genetic resources, and associated traditional knowledge during a historic Conference in Geneva, Switzerland, after decades of discussions.

(28 May  2024): Neuren Pharmaceuticals (ASX:NEU) has reported positive results from a Phase 2 trial of NNZ-2591 in children with Pitt-Hopkins syndrome.

(28 May  2024): Dimerix (ASX:DXB) has announced an exclusive license agreement with Taiba Middle East for the commercialisation of its candidate DMX-200.

(23 May  2024): Telix (ASX:TLX) has announced the successful completion of CUPID, a first-in-human Phase 1 dose escalation study of TLX592 in patients with advanced prostate cancer.

(21 May  2024): Australian clinical-stage immunotherapy company HaemaLogiX has announced the appointment of former health minister Greg Hunt to its board of directors.

(21 May  2024): An $8 million, 10-year philanthropic investment will spearhead new treatments for pancreatic cancer and create a new dedicated research centre at WEHI.

(21 May  2024): A new clinical trial centre launched in Melbourne hopes to bring more international trials to Victoria and give people with vision loss and blindness early access to investigative therapies.

(14 May 2024): The Therapeutic Goods Administration (TGA) is seeking industry feedback on the proposed changes to the regulation of exempt medical devices and exempt Other Therapeutic Goods (OTGs).  

(14 May  2024): AdAlta (ASX:1AD)  has announced an agreement under which Cell Therapies will be established as the preferred manufacturing partner of its cellular immunotherapies.

(14 May  2024): PYC Therapeutics (ASX:PYC) says that one of its candidates for a blinding eye disease of childhood called Autosomal Dominant Optic Atrophy has demonstrated disease-modifying potential in ‘retina in a dish’ models.

(9 May  2024): Novartis has partnered with Monash University and Monash Health for a project targeting cardiovascular disease.

(9 May  2024): The University of Queensland has announced that a new research and manufacturing hub has started work on a range of potential precision cancer treatments.

(7 May  2024): CUREator by Brandon BioCatalyst has announced the deployment of $7.21 million in funding to support eight biotechnology companies across their clinical and preclinical streams.

(7 May  2024): CEO Swami Raote said, “We are pleased to welcome Lior to our Global Executive Team and look forward to his active engagement as we keep scaling our geographic presence, expand our capacity, new products, and partnerships portfolio.”

(30 April  2024): Alterity Therapeutics (ASX:ATH) has announced that new data on its lead drug candidate, ATH434, was presented at the World Orphan Drug Congress USA 2024 in Boston.

(30 April  2024): FivepHusion has announced that the Human Regulatory Ethics Committee has approved the next clinical trial of Deflexifol.

(30 April  2024): Opyl (ASX:OPL) has confirmed the recent expansion of its TrialKey.ai AI-driven platform. It says this marks a significant milestone in clinical trial prediction and design optimisation.

(30 April  2024): Mesoblast (ASX:MSB) has announced that Joseph Swedish has chosen to step down as chair and will remain on the board until completion of his term at the company's annual general meeting later this year.

(23 April 2024): Bristol Myers Squibb has joined Brandon Capital, a leading Australian life sciences private equity firm, in supporting Pathios Therapeutics' Series B financing.

(23 April 2024): Noxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further investigation and development."

(23 April 2024): The Albanese Government has announced that the National Health and Medical Research Council will invest $5 million in six research projects focused on telehealth.

(18 April  2024):  Telix Pharmaceuticals (ASX:TLX) has reported an 18 per cent increase in revenue for the first three months of the calendar year 2024.

(18 April  2024):  Immutep Limited (ASX:IMM) has entered into an agreement with the Centre for Human Drug Research (CHDR) in the Netherlands to perform a first-in-human clinical study of IMP761.

(16 April  2024): Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has announced the first treatment utilising the OncoSil device on a patient residing in Turkey.

(16 April  2024): Next Science (ASX:NXS) has announced the publication of a study it says demonstrates the efficacy of XPERIENCE in decreasing periprosthetic joint infection following a Total Knee Arthroplasty.

(16 April  2024): The US FDA has granted fast-track designation to Telix Pharmaceuticals (ASX:TLX) investigational glioma imaging product Pixclara (TLX101-CDx).

(9 April  2024): Australian company Starpharma (ASX:SPL) has announced a strategic partnership with Medicxi to co-found a new UK-based company called Petalion Therapeutics.

(9 April  2024): Biotron has announced preliminary analyses of data from the BIT225-010 Phase 2 clinical trial of its lead antiviral drug BIT225.

(4 April  2024): Australian rare disease company Percheron Therapeutics has provided an update on its ongoing international phase 2b clinical trial of ATL1102 in Duchenne muscular dystrophy.

(4 April  2024): Clinical stage immunooncology company Imugene (ASX:IMU) has received a Notice of Grant from the Chinese Patent Office, following earlier Grants in Japan and South Korea.

(4 April  2024):  “It’s a privilege to join the Board of Opthea at such a transformative time,” said Sujal Shah. “I look forward to partnering with the executive leadership team and the Board as we continue to drive sozinibercept forward, with the goal of enhancing vision outcomes for patients worldwide.”

(2 April  2024):  Optiscan Imaging (ASX:OIL) has announced the establishment of its US Regional Office in Rochester, Minnesota, and the appointment of two US-based heads of clinical and regulatory affairs.

(26 March  2024): Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced a fully underwritten $121 million equity raising comprising a pro-rata accelerated non-renounceable entitlement offer and placement to institutional investors.

(26 March  2024): Race Oncology (ASX:RAC) has announced that a Certificate of Analysis has been issued for the first current Good Manufacturing Practice batch of its proprietary bisantrene formulation, RC220.

(26 March  2024): Cochlear (ASX:COH) has announced that Yasmin Allen AM is resigning from its board as an independent non-executive director.

(26 March  2024): Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study.

(21 March  2024): "Last year, we were delighted with the calibre of applicants and witnessed the remarkable potential of Australian researchers to contribute to the field of mRNA medicine," said Dr Craig Rayner, director of Moderna's Regional Research Centre for Respiratory Medicines and Tropical Diseases.

(19 March  2024): Australia’s national science agency, CSIRO, has announced Dr Debbie Eagles’ appointment to director of the Australian Centre for Disease Preparedness.

(19 March  2024): Telix has entered into an agreement to commercially partner the QDOSE dosimetry software platform with Germany-based contract research organisation Advanced Pharmaceutical Services Forschungsgesellschaft and its partner, Stockholm-based Quantinm.

(14 March  2024): Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease.

(14 March  2024): LBT Innovations (ASX:LBT) has announced the successful completion of primary validation for the APAS PharmaQC product.

(12 March  2024): Australian cell medicine company Mesoblast (ASX:MSB) has announced that the US FDA supported an accelerated approval pathway for the company's rexlemestrocel-L.

(12 March  2024): The company said the data builds on the positive clinical results reported to date which demonstrate this new class of biomimetic valve outperforms the market leader, returning patients to a near normal blood flow state.

(7 March  2024): AdAlta (ASX:1AD) has announced results from its Phase 1 extension study of lead asset AD-214 in development for fibrotic diseases, including the debilitating and fatal disease Idiopathic Pulmonary Fibrosis.

(7 March  2024): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has shared additional data from its diagnostic Cu-SAR-bisPSMA trial, COBRA.

(7 March  2024): Predictive diagnostics company Proteomics International Laboratories (ASX:PIQ) has successfully retained its ISO 13485 certification, an internationally recognised standard for safety and quality management systems in the manufacture of medical devices.

(5 March  2024):  Telix (ASX:TLX) will acquire radioisotope production technology firm ARTMS, its advanced cyclotron-based isotope production platform, manufacturing plant and a stockpile of ultra-pure rare metals required for consumable target production.

(5 March  2024):  Invion (ASX:IVX) has announced the findings of a study by the Peter MaCallum Cancer Centre on the effect of its INV043, when combined with an immune checkpoint inhibitor therapy.

(29 February 2024): Neuren Pharmaceuticals (ASX:NEU) has reported highlights from the fourth quarter 2023 earnings announcement and its partner Acadia Pharmaceuticals' conference call.

(27 February 2024): Telix (ASX:TLX) has announced total group revenue of $502.5 million for the 12 months to the end of December, up 214 per cent on the previous year.

(27 February 2024): Dimerix (ASX:DXB) has announced that data from the first 72 patients randomised in the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) has successfully been collected.

(22 February 2024): Australian medical technology company LBT Innovations (ASX:LBT) has announced the delivery of its APAS PharmaQC to Thermo Fisher Scientific.

(20 February 2024): Certa Therapeutics has announced that the US FDA has granted Fast Track Designation for its investigational therapy FT011 for treating systemic sclerosis.

(20 February 2024): Monash University is to lead a transdisciplinary consortium to develop and commercialise a suite of revolutionary and life-changing implantable cardiac devices that, for the first time, will offer longer-term solutions for all types of debilitating heart failure.

(15 February 2024): Brandon BioCatalyst’s CUREator, in partnership with ANDHealth, is set to deliver a BioMedTech Incubator focused on developing research discoveries and medical innovations with commercial potential to address dementia and cognitive decline thanks to a $50 million grant from the federal government.

(15 February 2024): Clarity Pharmaceuticals (ASX:CU6) has announced positive results from its diagnostic 64Cu-SAR-bisPSMA trial, COBRA (NCT05249127).

(15 February 2024): Opthea (ASX:OPT) has announced that it has completed the enrolment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept in combination with aflibercept.

(15 February 2024): Australian clinical-stage drug development company Syntara (ASX:SNT) has announced a new Phase 2 trial evaluating the combination treatment of its SNT-5505 with chemotherapy in patients with low and intermediate-risk myelodysplastic syndrome.

(13 February 2024): CSL CEO and managing director Dr Paul McKenzie said, “Our strong first half result for the 2024 financial year was driven by CSL Behring’s exceptional performance across its portfolio, especially immunoglobulins. The plasma initiatives we have implemented are starting to drive gross margin recovery."

(13 February 2024): Immuron (ASX:IMC) has announced record sales of its over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract, Travelan.

(8 February 2024): Recce Pharmaceuticals (ASX:RCE) has signed a Memorandum of Understanding with Indonesian organisation PT Etana Biotechnologies to accelerate the development of the Australian company's anti-infective portfolio.

(8 February 2024): Cochlear (ASX:COH) has upgraded its earnings guidance following better-than-expected growth in implant revenue for the half year ended December 2023.

(8 February 2024): Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the first patient in the ADVENT-AML Phase 1B clinical trial in Acute Myeloid Leukemia has received treatment with CHM 0201 in combination with azacitidine and venetoclax.

(6 February 2024): FivepHusion has announced that a poster of the most recently completed deflexifol clinical trial was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

(30 January 2024): Arovella Therapeutics (ASX:ALA) has signed a global, exclusive license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center.

(30 January 2024): Starpharma (ASX:SPL) has announced the results of the post-market clinical study of its Viraleze nasal spray in participants with COVID-19.

(25 January 2024): Aravax, a clinical-stage biotechnology company developing a targeted immunotherapeutic for peanut allergy (PVX108), has closed its Series B funding round with a total of US$42.2 million.

(23 January 2024): Opthea (ASX:OPT) expects to receive the remaining US$35 million committed funds under the Development Funding Agreement with Carlyle and Abingworth.

(23 January 2024): Cell therapy company Chimeric Therapeutics (ASX:CHM) has received commitments totalling approximately $3.2 million relating to a shortfall in entitlement offer.

(23 January 2024): Regenerative medicine company AVITA Medical (ASX:AVH) has entered into an exclusive multi-year distribution agreement with Stedical Scientific to commercialise PermeaDerm Biosynthetic Wound Matrix in the US.

(19 December 2023): Neuren Pharmaceuticals (ASX:NEU) has announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome.

(19 December 2023): Cell therapy company Carina Biotech has announced the dosing of the first patient in a Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell therapy candidate CNA3103 for the treatment of adult patients with metastatic colorectal cancer.

(14 December 2023): The Australian company said the designation reflects the potential of its EnGeneIC EDV (EnGeneIC Dream Vector) for the treatment of pancreatic ductal adenocarcinoma.

(14 December 2023): Clinical-stage drug development company Syntara (ASX:SNT), formerly Pharmaxis, has commenced dosing in the final cohort of a phase 2 clinical trial studying its pan-LOX inhibitor SNT-5505 in patients with myelofibrosis.

(14 December 2023): CMAX Clinical Research will celebrate the 30th anniversary of continuous operations in South Australia on 16 December.

(14 December 2023): The Brooker Prize is a suite of three industry awards celebrating outstanding contributions in life sciences across diverse career paths.

(12 December 2023): AusBiotech has announced Professor Skerritt's appointment to its board. It has also announced that Dr Liz Dallimore, the CEO and managing director of Argenica Therapeutics, will join its board.

(12 December 2023): Health Security Systems Australia (HSSA), a division of the Australian public company DMTC, has announced plans to transition its leadership.

(12 December 2023): The Victorian Government is investing $2 million to support the commercialisation of a world-first technology to treat brain injuries.

(12 December 2023): Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies.

(7 December 2023): Neuren Pharmaceuticals (ASX:NEU) has announced that the enrolment of subjects in its Phase 2 clinical trial of NNZ-2591 in Pitt Hopkins syndrome has been completed.

(7 December 2023): Telix has announced that the first patient has been dosed in an early access program in the Netherlands for its investigational positron emission tomography imaging agent TLX250-CDx in clear cell renal cell carcinoma.

(7 December 2023): Microba Life Sciences (ASX:MAP) has announced initial unblinded data from the Phase 1 clinical trial of lead drug candidate MAP 315 in the company's Inflammatory Bowel Disease Therapeutic Program.

(7 December 2023): Clinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence its Phase 2 clinical trial of CYP-001 in patients with High-Risk acute Graft versus Host Disease at clinical centres in Turkey.

(5 December 2023): The Korean Ministry of Food and Drug Safety has approved Amplia Therapeutics' (ASX:ATX) clinical trial to test narmafotinib (AMP945) in combination with gemcitabine and abraxane in advanced pancreatic cancer patients.

(5 December 2023): Australian medical device company OncoSil Medical (ASX:OSL) has announced that the first patient has been treated in the PANCOSIL Investigator-Initiated Clinical Trial.

(30 November 2023): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the successful completion of the first stage of cohort three of the Phase 2/2a theranostic trial, SECuRE.

(30 November 2023): Microba Life Sciences (ASX:MAP) has announced that stage one activity screening for its autoimmune disease program has been completed on schedule with partner Ginkgo Bioworks.

(28 November 2023): Dimerix (ASX:DXB) has announced that Chinese National Medical Products Administration Center for Drug Evaluation has approved an Investigational New Drug application to commence recruitment for ACTION3 Phase 3 study of DMX-200 for focal segmental glomerulosclerosis kidney disease.

(28 November 2023): The Albanese Government has officially opened the $392 million Industry Growth Program that includes medical science as one of its priority target areas.

(28 November 2023): Health Minister Mark Butler has announced that the federal government will invest over $700,000 to support the development of a potential new treatment that targets a type of childhood brain cancer with no known cure or treatment options.

(23 November 2023): The Australian Cell & Gene Catalyst has issued its response to the federal government's health workforce scope of practice review.

(23 November 2023):  Alterity Therapeutics (ASX:ATH) has received binding commitments for a capital raising of $4.8 million before costs via a two-tranche placement of fully paid ordinary shares to Australian and international institutions and other unrelated sophisticated, professional or other exempt investors.

(23 November 2023): The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved vaccine.

(21 November 2023): Orthocell (ASX:OCC) has announced the final results from its clinical study comparing OrthoATI to surgery to treat severe, chronic, treatment-resistant lateral epicondylitis.

(21 November 2023): Anteris Technologies (ASX:AVR) has reported 30-day data from the US Early Feasibility Study for DurAVR Transcatheter Heart Valve.

(16 November 2023): Certa Therapeutics announced that it will present the results of its Phase 2 clinical trial of FT011 in patients with scleroderma at the American College of Rheumatology's annual scientific meeting in the US.

(16 November 2023): Alterity Therapeutics (ASX:ATH) has announced that new data related to ATH434 was presented at the Society for Neuroscience in the US.

(16 November 2023): The US FDA has granted Argenica Therapeutics' (ASX:AGN) ARG-007 Orphan Drug Designation for the treatment of Hypoxic Ischaemic Encephalopathy.

(14 November 2023): Telix Pharmaceuticals (ASX:TLX) has announced that the first patient has been dosed in its Phase 3 ProstACT GLOBAL study of its investigational prostate-specific membrane antigen targeting radio-antibody drug conjugate therapy, TLX591.

(14 November 2023): Neuren Pharmaceuticals (ASX:NEU) has announced that its Phase 2 clinical trial of NNZ-2591 for Phelan-McDermid syndrome has completed all study visits.

(14 November 2023): mRNA vaccines and therapies will be produced for clinical trials in a dedicated laboratory to be established at The University of Queensland.

(9 November 2023): Australian company Dimerix (ASX:DXB) has received an initial payment of €6.5 million ($10.7 million) from its partner, UK-based Advanz Pharma.

(9 November 2023): Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha in combination with paclitaxel has been completed with no safety or tolerability issues.

(9 November 2023): Radiopharmaceuticals company Clarity Pharmaceuticals (ASX:CU6) has announced that 50 patients have been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial, SABRE.

(1 November): A new report says the Australian biotechnology sector increased the country's economy by $9 billion because of the Federal Government's R&D Tax Incentive policy, according to a report commissioned by AusBiotech.

(1 November): Clinical-stage immuno-oncology company Imugene (ASX: IMU) has announced that its Phase 1 MAST (metastatic advanced solid tumour) trial evaluating the safety of novel cancer-killing virus CF33hNIS (VAXINIA) has cleared cohort 4 of the intravenous arm of the monotherapy dose escalation study.

(31 October 2023): Opthea (ASX:OPT) has announced that CEO Dr Megan Baldwin will transition to founder and chief innovation officer, appointing US-based executives Dr Frederic Guerard as CEO and Peter Lang as chief financial officer.

(31 October 2023): Emyria (ASX:EMD) has announced that its lead psychiatrists have received endorsement from an NHMRC-accredited ethics committee, allowing them to advance their authorised prescriber applications with the TGA.

(26 October 2023): Imugene (ASX:IMU) has announced that its CD19 oncolytic virotherapy drug candidate, onCARlytics, has commenced a Phase 1 clinical trial, with the first patient now dosed.

(26 October 2023): Anteris Technologies (ASX:AVR) has reported data from its US Early Feasibility Study for DurAVR Transcatheter Heart Valve, a new class of aortic valve replacement and the world’s only biomimetic, single-piece transcatheter aortic valve.

(24 October 2023): Australian company Immutep (ASX:IMM) has announced positive data from a trial of its LAG-3 immunotherapy, eftilagimod alpha, in combination with MSD's KEYTRUDA (pembrolizumab).

(24 October 2023): AdAlta (ASX:1AD), a clinical-stage company developing novel protein and cell therapeutic products from its i-body platform, has announced that all healthy volunteers in its AD-214 Phase 1 extension study have now successfully received three doses.

(24 October 2023): The US FDA has granted orphan drug designation for Certa Therapeutics' investigational therapy, FT011, for the treatment of systemic sclerosis (scleroderma).

(19 October 2023): “We are delighted to support RMIT and the next generation of nuclear medicine talent to bring this life changing technology to the people who need it most, through workforce training and development,” said Telix Director of Global Patient Advocacy and Government Affairs, Simone Leyden AM.

(17 October 2023): Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b study in T-cell lymphomas has been accepted for poster presentation at the American Society of Hematology annual meeting in December.

(17 October 2023): The Murdoch Children's Research Institute (MCRI) is rolling out an Australian-first stem cell therapy trial for an extremely rare genetic condition.

(12 October 2023): Ophthalmology-focused biotechnology company, Oculus BioMed, has announced a collaboration agreement with The Centre for Eye Research Australia for the development of a therapeutic gene as a novel anti-VEGF therapy to advance 'SwitchGene'.

(12 October 2023): Arovella Therapeutics (ASX:ALA) has signed a global, exclusive license agreement with Sparx Group for the use of a novel monoclonal antibody sequence targeting Claudin 18.2  in cell therapies.

(10 October 2023): David Ranson, executive chairman of FivepHusion, said, “As we pursue late clinical-stage development of our lead drug Deflexifol, augmenting and expanding the diversity and skill set of our Board is paramount to optimally positioning our company for global development activities and commercialisation."

(5 October 2023): The US FDA has granted Orphan Drug Designation status to Noxopharm's (ASX:NOX) CRO-67 preclinical drug candidate for the treatment of pancreatic cancer.

(5 October 2023): Advanz Pharma and Dimerix (ASX:DXB) have announced they have entered into an exclusive license agreement for the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand for the commercialisation of Dimerix’s Phase 3 drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis kidney disease.

(5 October 2023): CSL’s Research Acceleration Initiative has awarded new partnerships with a potential $500,000 investment in each program over two years.

(3 October 2023): Significant changes for Pharmaxis (ASX:PXS) with the company announcing a new name and the sale of the mannitol respiratory business.

(3 October 2023): PolyNovo (ASX:PNC) has received additional funding of US$10 million from the US Biomedical Advanced Research and Development Authority for the pivotal trial program of NovoSorb BTM.

(28 September 2023): Researchers at The University of Queensland are harnessing the latest sequencing technology developed by UK-based biotech Oxford Nanopore Technologies to analyse mRNA vaccines and therapies.

(28 September 2023): A national team of experts will advance an innovative biopolymer particle-based platform technology to develop vaccine candidates to protect against biowarfare threats, including Q Fever, tularaemia, and melioidosis.

(28 September 2023): Starpharma (ASX:SPL) has announced the presentation of data that it says demonstrate the benefits of combining its DEP irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in models of human colorectal cancer.

(26 September 2023): Dimerix (ASX:DXB) has announced that the US FDA has given conditional approval for the brand name QYTOVRA for its Phase 3 clinical drug candidate.

(26 September 2023): Australian medical device company PolyNovo (ASX:PNV) has announced that it more than doubled its revenue in August compared to the same month last year.

(21 September 2023): Emyria (ASX:EMD) has announced that it has secured a locally available supply of MDMA through a collaboration with Mind Medicine Australia and the Australian National University.

(21 September 2023): BioCurate, the independently operated joint venture between The University of Melbourne and Monash University, has announced the renewal of its partnership with Takeda.

(14 September 2023): Immutep (ASX:IMM) has announced the regulatory authorisation of eftilagimod alpha manufactured at commercial 2,000L scale for clinical trials across multiple countries, including Germany, Belgium, Denmark, and the UK.

(19 September 2023): Moderna has celebrated a half-way milestone for its Australian mRNA vaccine manufacturing facility nine months after breaking ground on the construction site in the Monash Technology Precinct in Melbourne.

(19 September 2023): Optiscan Imaging (ASX:OIL) has provided an interim readout on its Breast Cancer Intraoperative Assessment Study.

(14 September 2023): Australian company Starpharma (ASX:SPL) has announced it will present positive interim data from the trial of its DEP irinotecan at a key international oncology conference in October in the US.

(14 September 2023): Vaccine technology company Sementis has announced the appointment Dr Anne Collins as its new chief executive officer.

(14 September 2023): Adapt Ideations has announced the appointment of Cheryl Vance as its chief operating officer.

(14 September 2023): An early diagnostic test of oesophageal cancer developed in Western Australia has correctly identified 89 per cent of patients with the disease in the latest results.

(12 September 2023): Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the grant of a new patent for its PD1-Vaxx clinical drug candidate.

(12 September 2023): BCAL Diagnostics (ASX:BDX) says it has met a major milestone in its development pathway to launching a blood test for breast cancer. 

(7 September 2023): The company said the funds raised will be used to progress its Phase 2 clinical trial program, including completion of the XanaCIDD trial of Xanamem in patients with cognitive impairment associated with depression.

(7 September 2023): FivepHusion has announced that the first patient has commenced treatment as part of the Deflexifol at Relapse Trial.

(5 September 2023): Emyria (ASX:EMD) has secured commitments from new and sophisticated investors to raise $2 million and will initiate a non-renounceable pro rata entitlement offer to raise approximately $3.1 million.

(31 August 2023): Clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the US Department of Defence to support ongoing research and development of INNA-051.

(31 August 2023): Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced the appointment of Eric Sullivan as a non-executive director.

(31 August 2023): Global contract development and manufacturing organisation Vetter has been awarded Frost & Sullivan’s 2023 Global Customer Value Leadership Award in the aseptic fill-and-finish market.

(31 August 2023): Pharmaxis (ASX:PXS) has announced the publication in the journal Nature Cancer of preclinical results showing pan-Lysyl Oxidase inhibitor PXS-5505 increases survival by 35 per cent compared to chemotherapy treatment alone in the treatment of pancreatic ductal adenocarcinomas.

(29 August 2023): The liquidators of Ellume in Australia have appointed Gordon Brothers Ritchie Bros. Alliance to oversee the sale and auction of the company's diagnostic test kit production facility, cutting-edge R&D Laboratory Equipment, and inventory assets.

(29 August 2023): Botanix Pharmaceuticals (ASX:BOT) has announced that its chief operating officer has been appointed as its chief executive officer.

(29 August 2023): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the dosing of the first participant at the highest dose level of 12GBq in the third cohort of its theranostic trial evaluating 67Cu SAR-bisPSMA in patients with prostate cancer.

(24 August 2023): Clinical-stage biotechnology company Vaxxas has announced it will receive $5.4 million from the global charitable foundation Wellcome to conduct initial studies and a  Phase I clinical trial for a potential second-generation typhoid vaccine.

(24 August 2023): Telix (ASX:TLX) has reported total revenue of $220.8 million for the six months to the end of June 2023, driven by growth in prostate cancer imagined agent Illuccix.

(24 August 2023): Clinical-stage biopharmaceutical company Opthea (ASX:OPT) has announced that it is seeking to raise $80 million through a $10 million private placement and a $70 million entitlement offer.

(17 August 2023): Brandon BioCatalyst with ANDHealth are inviting expressions of interest for funding under the newly-created $50 million CUREator+ program.

(17 August 2023): Australian company Imugene (ASX:IMU) has agreed with US-based Precision Biosciences to acquire a worldwide exclusive license to its azer-cel allogeneic CD19 CAR-T cell therapy program.

(17 August 2023): Australian company Biotron (ASX:BIT) has announced that all participants in the Phase 2 COVID-19 clinical trial of its antiviral drug BIT225 have completed dosing, marking the end of the clinical phase of the study.

(15 August 2023): A big day for Moderna, with the company unveiling a new pharmacology accelerator with Monash University and a new corporate headquarters and regional research centre in Melbourne

(15 August 2023): CEO and managing director Dr Paul McKenzie said, “Our strong performance in the 2023 financial year was delivered against a challenging operating environment."

(15 August 2023): Cell therapy company Chimeric Therapeutics (ASX:CHM) has reported positive in-vitro data for CHM 0301, its next-generation armoured natural killer cell platform.

(10  August 2023): An Australian-developed vaccine candidate developed at QIMR Berghofer has achieved potent and durable immune protection against Epstein–Barr virus.

(10  August 2023): Merck recently travelled to the Northern Territory with the DeadlyScience team to pilot the first DeadlyLabs kit.

(10  August 2023): Clinical stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the completion of cohort two and advancement to cohort three in the dose escalation phase of its Phase 1/2 theranostic trial, SECuRE.

(8  August 2023): Dimerix (ASX:DXB) has announced that the independent Data Safety Monitoring Board has successfully concluded a second review of the ACTION3 phase 3 clinical trial.

(3  August 2023): Australian clinical-stage biotechnology company Immutep (ASX:IMM) says it has received positive scientific advice from the European Medicines Agency for the continued development of its soluble LAG-3 protein and first-in-class MHC Class II agonist, eftilagimod alpha.

(3 August 2023): The Peter MacCallum Cancer Centre has become the first hospital in Victoria to offer accessible digital wayfinding for patients, staff, and visitors, through its hospital-wide launch of the Australian digital solution, BindiMaps.

(1 August 2023): Allarity Therapeutics and Detsamma Investments, which trades as FivepHusion, have announced a clinical collaboration agreement.

(1 August 2023): The nation’s largest cancer genomics initiative was launched in Sydney last week with the goal of saving or extending the lives of thousands of Australians battling incurable or advanced cancers, including ovarian, pancreatic and sarcomas.

(27 July 2023): Clinical-stage Australian biotech company HaemaLogiX has entered into a co-development agreement with the Peter MacCallum Cancer Centre to conduct the first-in-human Phase 1 trial of its CAR-T immunotherapy, KMA.CAR-T, for kappa-type multiple myeloma.

(27 July 2023): Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the Japan Patent Office has issued a Notice of Allowance for application JP2022007016A.

(25 July 2023): Dimerix (ASX:DXB) has confirmed that the first 72 patients have been randomised in its DMX-200 ACTION3 phase 3 trial in patients with FSGS kidney disease.

(20 July 2023): "We’re thrilled to expand BioCurate’s network of international strategic partners through this new agreement with NLC," said BioCurate chair, The Hon. John Brumby AO.

(20 July 2023): Australian company Telix has announced that the first patient has been dosed in a Phase 1 study of its investigational targeted radiation therapy, TLX250, combined with Merck's DNA-dependent protein kinase inhibitor candidate, peposertib.

(18 July 2023): Neuren Pharmaceuticals (ASX:NEU) has announced the global expansion of its partnership with US company Acadia Pharmaceuticals for DAYBUE (trofinetide).

(18 July 2023): Actinogen Medical's (ASX:ACW) chief medical officer, Dr Dana Hilt, has presented an academic poster to the Alzheimer’s Association International Conference in Amsterdam.

(18 July 2023): Lumos Diagnostics (ASX:LDX) has signed an agreement with Henry Schein Medical for the FebriDx point-of-care test. 

(13 July 2023): Pharmaxis (ASX:PXS) has announced details of a final interim analysis of data from ten patients who have completed six months treatment with PXS-5505.

(13 July 2023): The Victorian government has invited expressions of interest for its 'Made in Victoria – Industry R&D Infrastructure Fund'.

(11 July 2023): AdAlta (ASX:1AD) has released new data on the potential efficacy of AD-214 in humans with Idiopathic Pulmonary Fibrosis and other fibrotic diseases.

(11 July 2023): Kazia Therapeutics (ASX:KZA) has announced that its lead program, paxalisib, has been awarded Fast Track Designation by the US FDA.

(11 July 2023): Recce Pharmaceuticals (ASX:RCE) has announced that its Phase 1/2 clinical trial evaluating R327 at faster infusion rates has successfully dosed its first cohort of male and female subjects.

(11 July 2023): Lumos Diagnostics (ASX:LDX) says it has received firm commitments from institutional investors to raise approximately $4.75 million in proceeds from a placement.

(6 July 2023): International research led by QIMR Berghofer has found hundreds of new genes linked to a person’s risk of developing glaucoma.

(4 July 2023): Dimerix (ASX:DXB) has announced that the Paediatric Committee of the European Medicines Agency has accepted its Paediatric Investigation Plan for the development of DMX-200 for focal segmental glomerulosclerosis following the PDCO meeting on 23 June 2023.

(6 July 2023): Moderna has submitted its vaccine for the prevention of RSV-associated lower respiratory tract disease and acute respiratory disease to regulatory agencies, including Australia's TGA.

(4 July 2023): Australian clinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has announced the appointment of Dr Kilian Kelly as its new CEO and managing director.

(4 July 2023): Australian diagnostics company, Nutromics, has raised $11 million in an acceleration round for its medical wearable diagnostic platform.

(29 June 2023): Australian company Microba Life Sciences (ASX:MAP) has announced that the first participants have been successfully dosed in a phase 1 clinical trial of its candidate for inflammatory bowel disease.

(29 June 2023): Neuren Pharmaceuticals (ASX:NEU) has announced that the first site in the US for its Phase 2 clinical trial of NNZ-2591 in Prader-Willi syndrome is now open.

(29 June 2023): Telix (ASX:TLX) has released further details of the positive results from its completed pivotal Phase 3 ZIRCON study of TLX250-CDx in clear cell renal cell carcinoma.

(27 June 2023): EpiAxis Therapeutics has announced the nomination of epiresatide as its flagship candidate for investigational new drug advancement.

(27 June 2023): Health minister Mark Butler has announced $73 million in grants for 19 projects to develop and implement new medical technologies or to build or upgrade facilities for cutting-edge health and medical research.

(22 June 2023): Australia’s newest biotech incubator is calling for innovative early-stage Australian biotechnology companies to take up residency in its new Melbourne-based facility.

(22 June 2023):  Imagion Biosystems (ASX:IBX) has announced the appointment of Dr Isaac Bright as its new CEO

(20 June 2023): Australian company Vaxxas has announced the opening of its global headquarters and manufacturing facility in Brisbane.

(20 June 2023): CSIRO board chair Kathryn Fagg AO said, “Professor Hilton will be a great asset to CSIRO, as the national science agency strives to solve our greatest challenges."

(20 June 2023): Regenerative medicine company AVITA Medical (ASX:AVH) has announced that the US FDA has approved its application for the premarket approval of its RECELL System for the treatment of vitiligo.

(20 June 2023): Telix (ASX:TLX) has announced that the first patient has been dosed in a global Phase 2 study of its imaging agent TLX250-CDx (89Zr-DFO-girentuximab).

(15 June 2023):  FivepHusion said the collaboration is designed to strategically and optimally progress the development and commercialisation of its enhanced chemotherapeutic formulation of deflexifol.

(15 June 2023):  Starpharma (ASX:SPL) has announced the recent presentation of AZD0466 clinical data by AstraZeneca at the European Hematology Association 2023 Hybrid Congress.

(13 June 2023): Telix (ASX:TLX) has officially opened its radiopharmaceutical production facility in Brussels South (Seneffe), in the Wallonia region of Belgium.

(13 June 2023): Anteris Technologies (ASX:AVR) recently presented new patient data at the TVT conference showing that DurAVR THV maintained positive haemodynamic performance at 30 days, as reported with this patient cohort at 48 hours post-procedure.

(8 June 2023): Australian company Neuren Pharmaceuticals (ASX:NEU) has received the US$40 million milestone payment of US$40 million from Acadia for the US approval and first sale of its treatment for Rett syndrome.

(8 June 2023): Australian company Vaxxas, which is developing a novel vaccination platform technology, has appointed a former senior Pfizer executive as its chief medical officer.

(6 June 2023): Australian company Aravax has announced that the first patient has been dosed in its Phase 2 study (AVX-201) of investigative candidate PVX108 for the treatment of peanut allergy.

(6 June 2023): Starpharma (ASX:SPL) has announced that it has achieved regulatory approval for its antiviral nasal spray product, Viraleze, in Malaysia.

(6 June 2023): Anatara Lifesciences (ASX:ANR) has provided an update on the Gastrointestinal ReProgramming trial for irritable bowel syndrome.

(1 June 2023): Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced a new clinical trial agreement for the CHM 1101 Phase 1B clinical trial in glioblastoma at the Sarah Cannon Transplant and Cellular Therapy Program at St David’s South Austin Medical Center in the US.

(1 June 2023): Imugene (ASX:IMU) has announced that the first patient has been dosed in the combination cohort of the IMPRINTER trial.

(1 June 2023): Cannabinoid company Zelira Therapeutics (ASX:ZLD) has announced the appointment of Dr Donna Gentile O’Donnell as a non-executive director.

(1 June 2023): Optiscan Imaging (ASX:OIL) has launched an entitlement offer to raise $16.7 million it says will be used to support its strategic portfolio expansion

(30 May 2023): Australian regenerative medicine company Orthocell (ASX:OCC) has appointed John Van Der Wielen as independent non-executive chairman.

(30 May 2023): Immutep (ASX:IMM) has announced it has entered into an agreement under which Charles River will conduct a GLP toxicology study for IMP761.

(30 May 2023): Kazia Therapeutics (ASX:KZA) recently attended and participated in the Cancer Moonshot Brain Cancers Forum on Glioblastoma and Diffuse Intrinsic Pontine Glioma at the White House in Washington DC.

(30 May 2023): GreenLight Clinical, a physician-led Clinical Research Organisation and laboratory, has announced that Dr Robert Lin has been appointed its chief executive officer.

(23 May 2023): OncoSil Medical (ASX:OSL) has announced the first patient treatment in Italy with its OncoSil device.

(25 May 2023): Pharmaxis (ASX:PXS) has announced that a phase 1c trial of its novel topical drug treatment for scarring has met its primary safety objective and two secondary biomarker endpoints in patients with established scars.

(23 May 2023): Amplia Therapeutics (ASX:ATX) has received grant funding to undertake a research collaboration with Australia’s national science agency CSIRO to develop novel topical formulations of the company’s FAK inhibitors.

(23 May 2023): ANDHealth Activate, the first dedicated digital and connected health accelerator program supported by LaunchVic, has announced the 15 digital and digitally-enabled medical technology companies that will benefit from this new program.

(18 May 2023):  Immutep (ASX:IMM) has reported positive results from a clinical trial of its LAG-3 immunotherapy in combination with MSD's PBS-listed anti-PD-1 therapy KEYTRUDA (pembrolizumab).

(18 May 2023): Optiscan Imaging (ASX:OIL) has announced the publication of readout results of its oral cancer imaging study conducted by Dr Camile Farah and his team at the Australian Centre for Oral Oncology Research and Education.

(18 May 2023):  Silverstone Developments’ development application for a life sciences building at 37-41 Butterfield Street, Herston, has been approved by Brisbane City Council.

(18 May 2023): Avecho Biotechnology (ASX:AVE) has commenced manufacturing activities to support its pivotal Phase 3 clinical trial with the US-based contract manufacturing organisation, Procaps Group.

(16 May 2023): Clinical stage cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that it has received commitments from its board and management team to raise $1.04 million under a placement of new shares in the company.

(11 May 2023): Amplia Therapeutics (ASX:ATX) has announced the completion of enrolment of the third cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial in frontline patients with pancreatic cancer.

(9 May 2023): Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received approval from the US FDA to proceed with the clinical evaluation of the new oral therapeutic targeting campylobacter and enterotoxigenic Escherichia coli.

(9 May 2023): Telix (ASX:TLX) has agreed with Bayer to supply its Illuccix for a Phase 3 ARASTEP study investigating the efficacy of the German company's Nubeqa (darolutamide) plus androgen deprivation therapy in hormone-sensitive prostate cancer.

(9 May 2023): Antisense Therapeutics (ASX:ANP) has announced the appointment of Dr James Garner as its new chief executive officer and managing director.

(9 May 2023): Australian medical technology company LBT Innovations (ASX:LBT) has announced that its chair, Joanne Moss, will retire from its board in the coming months.

(4 May 2023): Cell therapy immuno-oncology company Carina Biotech has announced a poster presentation showcasing its planned Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell therapy candidate CNA3103 in patients with metastatic colorectal cancer.

(4 May 2023):  Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the Indian Patent Office has issued a patent covering certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including the company's clinical-stage CAR-T asset CHM 1101 and preclinical stage CAR-NK asset CHM.

(2 May 2023): Cytiva and the University of Adelaide are collaborating with BioCina, an Australian-based multi-product biologics contract development and manufacturing organisation, to expand its facility in Adelaide to manufacture mRNA-based vaccines and therapies.

(2 May 2023): Immutep (ASX IMM) has received regulatory approval from the Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines, to initiate a new investigator-initiated trial of eftilagimod alpha.

(27 April 2023): Medical device company OncoSil (ASX:OSL) has announced the findings of an oral presentation at The Mayo Clinic IMPACT Course 2023 by Dr Frank Weilert from Waikato Hospital in New Zealand.

(27 April 2023): Emyria (ASX:EMD) has added to its pipeline with the inclusion of a high potency and highly bioavailable ultra-pure cannabidiol dose form to its proprietary cannabinoid medicine pipeline, EMD-RX9.

(20 April 2023): Australian radiopharmaceutical company Telix (ASX:TLX) has delivered its first $100 million revenue quarter with soaring growth in the US.

(20 April 2023): Australian company Neuren Pharmaceuticals (ASX:NEU) is set to receive a US$40 million milestone payment following the US launch of its treatment for Rett syndrome.

(18 April 2023): Australian biomedical technology incubator Proto Axiom has announced a second round of financing of $5 million following its initial raise of $10 million last September.

(13 April 2023): Pharmaxis CEO Gary Phillips said, “The agreement with the FDA to expand the patient population in the ongoing Phase 2 study to include those patients currently on a JAK inhibitor is an important step forward in realising the benefits of lysyl oxidase inhibition for all myelofibrosis patients and in maximising the commercial opportunity for PXS‐5505."

(13 April 2023): Clinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has received approval from the Australian Human Research Ethics Committee to commence the proposed Phase 2 clinical trial in acute graft-versus-host disease.

(11 April 2023): Immutep (ASX:IMM), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, has announced that Lis Boyce has been appointed as a non-executive director.

(11 April 2023): Recce Pharmaceuticals (ASX:RCE) has announced that the Australian Patent Office has issued notification of intent to grant the first of its new 'Patent Family 4' for its anti-infectives 'Process for Preparation of Biologically Active Copolymer'.

(6 April 2023): Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has secured commitments to raise $10 million that will be used to progress its lead development program.

(6 April 2023): Alterity Therapeutics (ASX:ATH) has announced that the first participant has been dosed in the United Kingdom in the company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy.

(4 April 2023): Emyria (ASX:EMD) has entered into a binding Term Sheet with Aspen Pharmacare Australia to license and commercialise EMD-RX5.

(28 March 2023): Noxopharm (ASX:NOX) has announced the development of a new product candidate based on mRNA technology as part of the company’s Sofra preclinical platform.

(28 March 2023): IDT Australia (ASX:IDT) has announced that the TGA has expanded the licensing conditions covering its Aseptic Sterile Processing facility.

(28 March 2023): Clinical-stage radiotherapeutics company Radiopharm Theranostics has announced a new collaboration with GenesisCare under which they will seek to develop new treatments for some complex, hard-to-treat cancers.

(23 March 2023): Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) says that it has successfully completed a pre-Investigational New Drug meeting with the US FDA and has received "positive feedback" on the development plan for CHM 2101.

(21 March 2023): The federal government has selected Brandon BioCatalyst, in partnership with ANDHealth, to deliver the $50 million BioMedTech Incubator program.

(16 March 2023): Australian therapeutic antibody development company Patrys (ASX:PAB) has announced results from a recently completed pre-clinical study that it says validates the potential to use its full-size IgG deoxymab, PATDX3, for synthetic lethality strategies to treat relevant cancers.

(16 March 2023): Optiscan Imaging (ASX:OIL) has announced the interim results of its oral imaging study conducted at the Australian Centre for Oral Oncology Research and Education.

(16 March 2023): Proteomics International Laboratories (ASX:PIQ) has announced that it will resubmit its application to have the PromarkerD predictive test for diabetic kidney disease funded via Medicare.

(14 March 2023): A major win for Australian company Neuren Pharmaceuticals (ASX:NEU) with the US FDA approving its treatment for Rett syndrome.

(14 March 2023): Sanofi has opened the first tranche of senior medical research career opportunities available at its Translational Science Hub in Queensland.

(14 March 2023): Health minister Mark Butler has announced funding of $15 million for Monash University's mitochondrial donation pilot program, mitoHOPE.

(14 March 2023): Immutep (ASX:IMM) has announced the initiation of the AIPAC-003 clinical trial evaluating its eftilagimod alpha in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer.

(9 March 2023): The Brandon BioCatalyst-managed Women in Leadership Development program has announced the latest cohort of participants and confirmed additional funding from the federal government.

(9 March 2023): Bionomics (ASX:BNO) has announced the release of an analysis of the data from its Phase 2 PREVAIL study evaluating the efficacy and safety of BNC210 for the treatment of acute Social Anxiety Disorder.

(9 March 2023): Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that the US FDA has granted Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas, including cutaneous TCL.

(9 March 2023): Cell therapy company Chimeric Therapeutics (ASX:CHM) has completed the manufacturing and quality release for CHM 2101 viral vector.

(7 March 2023): GreenLight Clinical and Cure Therapeutics have conducted a signing ceremony in Sydney with the two companies looking to collaborate on the evaluation of potential cancer therapy.

(7 March 2023): Starpharma (ASX:SPL) has announced the appointment of Justin Cahill as its chief financial officer and company secretary.

(7 March 2023): Clinical-stage company Emyria (ASX:EMD) has announced a collaboration with a leading multidisciplinary, psychiatrist-led clinical service specialising in complex trauma treatment, The Pax Centre.

(2 March 2023): CSL Seqirus has signed an exclusive license and distribution agreement to commercialise Amarin's VAZKEPA (icosapent ethyl) in Australia and New Zealand.

(2 March 2023): Microba Life Sciences (ASX:MAP) has announced new agreements with SYNLAB International affiliate organisations to distribute its testing technology in Turkey and Czech Republic.

(2 March 2023): Neuren Pharmaceuticals (ASX:NEU) has announced the appointment of Joe Basile as an independent non-executive director.

(28 February 2023): The Peter MacCallum Cancer Centre and Cartherics have announced a new collaboration to develop the company's autologous CAR-T cell therapy for the treatment of ovarian cancer.

(28 February 2023): CSL said that results from the trial showed that once-monthly subcutaneous injections of the first-in-class garadacimab significantly reduced the attack rate compared to placebo.

(28 February 2023): Medicinal cannabinoid and psychedelic medicine company Incannex Healthcare (ASX:IHL) has commenced a Phase 2 clinical trial to assess the safety and efficacy of its anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis.

(23 February 2023): A clinical trial has demonstrated that a technology developed by Australian company Cyban has produced similar results to invasive intracranial pressure monitoring.

(23 February 2023): Avecho Biotechnology (ASX:AVE) has announced that its ongoing collaboration with the Lambert Initiative at the University of Sydney will expand to include a series of clinical trials examining new clinical indications for cannabidiol using the company's CBD soft-gel capsule.

(23 February 2023): Noxopharm (ASX:NOX) has announced that research from its inflammation-related Sofra preclinical program will be presented orally at the upcoming 15th International Congress on Systemic Lupus Erythematosus.

(23 February 2023): The TGA has granted provisional approval to Moderna’s bivalent COVID-19 vaccine, SPIKEVAX, for use as a booster dose in individuals aged 12 years and older.

(21 February 2023): Brisbane MedTech businesses have won international recognition after securing top prizes at a shark-tank-style pitch challenge in San Francisco.

(21 February 2023): The company said that in an ongoing clinical trial, HEMGENIX reduced the rate of annual bleeds with a single infusion by delivering a functional gene that acts as a blueprint for coagulation Factor IX.

(21 February 2023): The executive of the Agricultural Biotechnology Council of Australia has announced that Dr Joe Smith has accepted another term as chair for two years.

(16 February 2023): CSL's largest franchise has delivered 19 per cent revenue growth for the six months to the end of December 2022 with the company reporting an overall net profit after tax of $1.62 billion.

(16 February 2023): Australian medical technology company Cochlear has announced a 9 per cent increase in revenue for the six months to the end of 2022

(16 February 2023): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced that its Phase 2 diagnostic 64Cu SARTATE trial for patients with known or suspected neuroendocrine tumours has reached the 50 per cent recruitment milestone.

(16 February 2023): Surface chemistry company AnteoTech (ASX:ADO) has announced the appointment of Tsui Min Lian to the newly created position of chief marketing officer.

(14 February 2023): AcuraBio has announced that it will provide a cGMP plasmid DNA contract development and manufacturing service using Cytiva’s new process platform technology.

(14 February 2023): Genetic Technologies (ASX:GTG) has announced the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment.

(09 February 2023): Certa Therapeutics has announced clinical trial data for its novel therapy for the treatment of serious inflammatory and fibrotic diseases.

(09 February 2023): Dimerix (ASX:DXB) has announced that an independent Data Safety Monitoring Board (DSMB) has successfully concluded a review of the ACTION3 phase 3 clinical trial.

(09 February 2023): Argenica Therapeutics (ASX:AGN) has released initial preclinical data on the ability of its ARG007 to inhibit human recombinant Amyloid-Beta aggregation in a preclinical model of Alzheimer’s disease.

(07 February 2023): Emyria (ASX:EMD) says it is "well positioned" to accelerate patient access to psychedelic substances following the TGA's decision to reclassify psilocybin and MDMA from 1 July this year.

(07 February 2023): Australian clinical-stage biotechnology company Immutep (ASX:IMM) has announced that the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with first-line Non-small cell lung cancer.

(07 February 2023): Genetic Technologies (ASX:GTG) has announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of American Depositary Shares to raise approximately US$5 million.

(07 February 2023): Optiscan Imaging has announced an exclusive collaboration with Canadian-based Prolucid Technologies to develop AI algorithms and telepathology workflows using its confocal laser endomicroscopy technology.

(02 February 2023): Agilex Biolabs is Australia’s largest regulated bioanalytical and toxicology laboratory. It is a member of the Healius network.

(02 February 2023): Genetic Technologies (ASX:GTG) has announced that it will form a strategic alliance with QIAGEN, a global leader in molecular testing with operations in 35 countries.

(02 February 2023): Antisense Therapeutics (ASX:ANP) has reported what it describes as initial positive muscle functional data from a DMD mdx animal study assessing the use of the combination of antisense to CD49d with a dystrophin exon skipping restoration drug.

(31 January 2023): Alterity Therapeutics (ASX:ATH) has announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective in a genetic model of Parkinson’s disease.

(31 January 2023): The Centenary Institute has announced the appointment of Professor Marc Pellegrini as its new executive director. 

(31 January 2023): Emyria (ASX:EMD) has announced that the first patients have been successfully dosed in its Phase 3 clinical trial for EMD-RX5.

(24 January 2023): Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that all patients dosed in the third cohort of a clinical trial have advanced beyond the 28-day follow-up period without experiencing dose-limiting toxicities.

(24 January 2023): Neuren Pharmaceuticals (ASX:NEU) has announced that the US FDA has reviewed Neuren’s Investigational New Drug application for NNZ-2591 in Prader-Willi syndrome.

(19 January 2023): Immuron (ASX:IMC) has updated on the US Department of Defense Uniformed Services University (USU) clinical evaluation of the company's Travelan.

(17 January  2023): Dimerix (ASX:DXB) has confirmed the outcomes of a meeting with the US FDA to discuss the paediatric plan for its DMX-200 in Focal Segmental Glomerulosclerosis patients under 18 years old.

(17 January 2023): The Victorian government is encouraging organisations and people in their mid-career stage to access opportunities under its 'Digital Jobs' and 'Digital Jobs for Manufacturing' programs.

(20 December 2022): Dimerix (ASX:DXB) has confirmed that the recruitment of the first 72 patients in its DMX-200 ACTION3 Phase 3 trial in patients with FSGS kidney disease has been achieved.

(20 December 2022): Australian medical technology company LBT Innovations (ASX:LBT) has announced the appointment of Thermo Fisher Scientific as the exclusive distributor for the APAS Independence in Europe.

(20 December 2022): Bionomics (ASX:BNO) has announced the results from its Phase 2 PREVAIL study to evaluate the safety, tolerability, and efficacy of BNC210 for the acute treatment of Social Anxiety Disorder.

(13 December 2022): CSL has announced the appointment of Dr Paul McKenzie to succeed Paul Perreault as its CEO and managing director from 6 March 2023.

(13 December 2022): An Australian researcher who is internationally recognised for her work on mapping the genetics of breast, ovarian and other cancers has been awarded the 2022 GSK Award for Research Excellence.

(08 December 2022): The facility, the largest of its kind in the Southern Hemisphere, is part of the company's $2 billion-plus capital investment currently underway in Australia.

(08 December 2022): Clinical research organisation Novotech has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific CRO industry.

(06 December 2022):  Tessara Therapeutics and NETRI have announced a collaboration to develop a family of next-generation organ-on-chip models for neurological disease.

(06 December 2022): Sanofi has announced a significant investment in Queensland with the company a dominant investor in a $280 million five-year mRNA Translational Science Hub with the University of Queensland, Griffith University and the state's government.

(06 December 2022): Australian company FivepHusion has announced what it describes as "important progress" towards developing its chemotherapy candidate Deflexifol.

(06 December 2022): Australian company Noxopharm (ASX:NOX) has provided an update on the IONIC Investigator-initiated pilot Phase 1 clinical trial of its lead oncology drug candidate Veyonda.

(06 December 2022): Australian vaccine development company Vaxxas has announced the appointment of Doug Cubbin as its chief financial officer.

(01 December 2022): Silverstone Developments has announced it is planning a seven-storey medical research facility with 11,700 square metres of purpose-built life sciences, research, medical technology, and education accommodation in Queensland’s largest health precinct, Herston.

(01 December 2022): Melbourne scientist Professor Alan Cowman AC has been awarded the 2021 CSL Florey Medal.

(01 December 2022): Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the publication of positive preclinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple forms of cancer.

(29 November 2022): Leading medical diagnostics provider Sonic Healthcare has taken a strategic 19.99 per cent stake in Microba Life Sciences.

(29 November 2022): Australian company (ASX:EMD)has been accepted into the US NIH HEAL Initiative National Institute of Neurological Disorders and Stroke Preclinical Screening Platform for Pain program.

(29 November 2022): Immutep (ASX:IMM) has announced a new clinical trial collaboration under which the Australian company's investigative LAG-3 immunotherapy, efti, will be studied with Merck and Pfizer's PBS-listed BAVENCIO (avelumab).

(24 November 2022): The US FDA has approved CSL's HEMGENIX (etranacogene dezaparvovec-drlb) as the first and only one-time gene therapy for appropriate adults with haemophilia B.

(24 November 2022): CatalYm has announced the closure of an oversubscribed Series C financing round that was co-led by new investors, Brandon Capital and Jeito Capital, with participation from a number of existing investors.

(22 November 2022): Australian company Technovalia and its partners Chulalongkorn University and BioNet have announced ethics approval for a phase 2 trial of the ChulaCov19 BNA159 mRNA vaccine as a booster dose in adults.

(22 November 2022): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the approval of its Investigational New Drug (IND) application by the US FDA to evaluate its SAR-Bombesin product for the identification and treatment of metastatic castrate-resistant prostate cancer (mCRPC). 

(22 November 2022): Zelira Therapeutics (ASX:ZLD) has announced the successful enrolment of 60 patients in the clinical trial of its cannabinoid medicine for diabetic nerve pain.

(15 November 2022): Australian company Telix has entered into an agreement with Sacramento-based Northern California PET Imaging Center to acquire Optimal Tracers.

(10 November 2022): Australian company Vaxxas has launched a phase one clinical trial of a needle-free COVID-19 vaccine candidate.

(10 November 2022): BiomeBank has announced the first regulatory approval for a donor-derived microbiome drug product worldwide.

(10 November 2022): Leading Australian life sciences venture capital firm, Brandon Capital, has invested in neuroscience company NRG Therapeutics as part of its £16 million ($29 million) series A financing.

(08 November 2022):  The Australian epigenetics company has signed an agreement with Seattle Children’s Research Institute in the US that aims to help researchers study a new approach to treating paediatric brain cancer.

(08 November 2022):

 

Australian biotechnology company Certa Therapeutics says new research presented by the University of Michigan has revealed ground-breaking results for its FT011.

(08 November 2022): Alterity Therapeutics has announced that a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) study was given at the recent American Autonomic Society Annual Conference.

(08 November 2022): Telix has announced "highly positive" top-line results from its pivotal Phase 3 ZIRCON study of its investigational kidney cancer positron emission tomography imaging agent, TLX250-CDx.

(01 November 2022): Regenerative medicine company Orthocell (ASX:OCC) has announced that its Remplir has been added to the federal government's Prostheses List.

(01 November 2022): A new report shows that Australia has moved ahead of the UK as a location for industry-initiated early and mid-phase clinical trials.

(20 October 2022):  Neuren Pharmaceuticals (ASX:NEU) has received the milestone payment of US$10 million from its US partner Acadia Pharmaceuticals.

(18 October 2022):  Therapeutic antibody development company Patrys (ASX:PAB) has announced new preclinical data for its full-sized IgG antibody, PAT-DX3.

(18 October 2022):  ANDHealth CEO and managing director Bronwyn Le Grice has been recognised in the 2022 Brilliant Women in Digital Health Awards as one of 25 women honoured for outstanding achievements and contributions in digital health.

(18 October 2022):  Telix (ASX:TLX) has announced that Health Canada has approved Illuccix gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localising tumour tissue in recurrent prostate cancer.

(13 October 2022):  DNA sequencing company Illumina has teamed up with AstraZeneca in a partnership that will seek to leverage artificial intelligence to enhance the drug discovery process.

(13 October 2022):  Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced what it describes as positive data from its BTX 1702 Phase 1b/2 papulopustular rosacea clinical study.

(11 October 2022):  Australian pharmaceutical manufacturing company IDT Australia (ASX:IDT) has announced the appointment of Mark Simari and Geoffrey Sam OAM to its board.

(11 October 2022):  “Australia provides excellent academic research, and we are looking forward to collaborating with world-class scientists and researchers to strengthen Australia’s mRNA ecosystem and to jointly develop potential novel treatments and vaccines for people worldwide," said BioNTech co-founder and CEO, Professor Ugur Sahin.

(6 October 2022):  Australian immunotherapy company Immutep has secured fast-track designation from the US FDA for its eftilagimod alpha for use in combination with MSD's KEYTRUDA (pembrolizumab).

(4 October 2022):  Australian biomedical technology incubator Proto Axiom has announced an initial fundraising of $10 million to progress its early-stage development of pre-clinical biotech opportunities.

(29 September 2022): Telix Pharmaceuticals (ASX:TLX) and GenesisCare, the largest provider of integrated cancer care in Australia, have announced that a first patient has been enrolled in the Phase 2 ProstACT TARGET study of prostate cancer antibody therapy candidate TLX591.

(29 September 2022): Agilex Biolabs has expanded its capacity to provide services to the biotechnology, pharmaceutical and animal health industry with the opening of its new in-vivo testing facility in Brisbane.

(29 September 2022): Each researcher will receive up to $500,000 over two years to fast-track the discovery of innovative biotherapies to address unmet medical needs.

(27 September 2022): The federal government's National Health and Medical Research Council will provide a $1 million grant to cell therapy company Cynata Therapeutics (ASX:CYP) under its Cardiovascular Health Mission.

(27 September 2022): Alterity Therapeutics (ASX:ATH) has announced a poster from the ongoing Biomarkers of Progression in Multiple System Atrophy natural history study was presented at the International Congress of Parkinson’s Disease and Movement Disorders.

(27 September 2022): Clinical-stage dermatology Botanix Pharmaceuticals (ASX:BOT) has submitted a New Drug Application to the US FDA for the approval of sofpironium bromide for patients with severe primary axillary hyperhidrosis.

(20 September 2022): Radiopharm Theranostics (ASX:RAD) has announced that the US FDA has granted Rare Pediatric Disease Designation for its DUNP19 technology for the treatment of osteosarcoma.

(20 September 2022): The US FDA has granted 510(k) clearance for PolyNovo's (ASX:PNV) NovoSorb MTX which provides soft tissue regeneration for the management of complex wounds.

(20 September 2022): Medibio non-executive director Dr Matt Mesnik said, “We are excited to have Dr Young join Medibio as its CEO. Tom has a tremendous background in healthcare as a provider, administrator, innovator and leader.”

(20 September 2022): Noxopharm (ASX:NOX) has announced the resignation of founder Dr Graham Kelly as a non-executive director in a move it describes as a natural evolution.

(15 September 2022): Australian cancer-focused epigenetics company EpiAxis Therapeutics has announced a collaboration with Canada’s largest and leading research hospital, the University Health Network (UHN), to study a new approach to prostate cancer treatment.

(15 September 2022): Noxopharm (ASX:NOX) has announced what it describes as encouraging new preclinical data from its long-term collaboration with UNSW Sydney.

(8 September 2022):  ANDHealth CEO and managing director Bronwyn Le Grice said, “This investment by the Victorian Government represents a significant commitment to growing a strong connected health sector, comprising both digital and digitally-enabled medical technologies."

(8 September 2022):  University of Queensland researchers have pioneered a new chemical process to manufacture the molecules that are the building blocks for lifesaving medicines, vaccines and energy storage materials.

(8 September 2022):  Antisense Therapeutics Limited (ASX:ANP) has announced that it intends to conduct a double-blind, placebo-controlled six-month dosing trial of ATL1102 followed by a six-month open-label phase 2b trial in non-ambulant boys with Duchenne’s Muscular Dystrophy.

(8 September 2022):  Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced that the first patient has been dosed in the nextHERIZON Phase 2 clinical trial.

(6 September 2022):  Melbourne-based company Esfam Biotech has been awarded $1 million in funding from the federal government's Medical Research Future Fund following its recent discovery in COVID-19 treatment research.

(6 September 2022):  A vaccine candidate developed by QIMR Berghofer Medical Research Institute against the common and potentially dangerous cytomegalovirus, or CMV, will be further developed in collaboration with US-based Dynavax Technologies Corporation.

(6 September 2022):  Recce Pharmaceuticals (ASX:RCE) has announced the appointment of Dr John Prendergast as its executive chairman.

(1 September 2022):  Cell therapy company Cynata Therapeutics (ASX:CYP) has announced the appointment of Janine Rolfe as an independent non-executive director.

(1 September 2022):  Starpharma (ASX:SPL) has been announced as the winner of the ‘Most Significant Commercial Outcome’ award following the completion of a Biomedical Translation Bridge program backed by the federal government’s Medical Research Future Fund and MTPConnect.

(1 September 2022):  Leading Australian biopharmaceutical CDMO, AcuraBio, has been acquired by investor Dr Glenn Haifer and Ampersand Capital Partners.

(30 August 2022):  The University of Sydney has announced its largest ever capital investment to build a leading biomedical precinct to fast-track research and patient care in New South Wales.

(30 August 2022):  A study led by Monash University and believed to be a world first has demonstrated that an Artificial Intelligence (AI) model can potentially predict the best personalised, anti-seizure medication for patients with newly diagnosed epilepsy.

(30 August 2022):  Optiscan Imaging (ASX:OIL) has announced the submission to the US FDA of a pre-market notification (510(k)) application for the InVivage device intended for oral tissue imaging.

(25 August 2022):  Biotron (ASX:BIT) has announced that a Phase 2 HIV-1 clinical trial of its lead antiviral drug, BIT225, is fully recruited.

(25 August 2022):  Analytical science and device company Trajan Group Holdings (ASX:TRJ) has reported its full-year results for the 2022 financial year with revenues up 40.5 per cent to $107.6 million.

(25 August 2022):  Clinical-stage oncology company developing personalised therapies Prescient Therapeutics (ASX:PTX) has announced a Share Purchase Plan (SPP) targeting to raise $8 million.

(25 August 2022):  Alterity Therapeutics (ASX:ATH) has announced that the Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy is now open for enrolment in the United Kingdom.

(23 August 2022):  Living Cell Technologies (ASX:LCT) has advanced its Parkinson’s disease research with choroid plexus tissue successfully shipped from New Zealand to Australia as part of the third clinical trial of NTCELL.

(23 August 2022):  Australian nuclear medicine company Telix Pharmaceuticals has reported a 726 per cent rise in revenue for the six months to the end of June.

(23 August 2022):  Antisense Therapeutics (ASX:ANP) has announced outcomes from its collaboration to study the neurological aspects of Long COVID-19 with US-based researchers.

(23 August 2022):  Dimerix (ASX: DXB) says the CLARITY 2.0 investigator-led study of COVID-19 patients has concluded recruitment.

(18 August 2022):  CSL has announced a net profit after tax of $2.255 billion for the 12 months ended 30 June 2022 and new carbon emission targets.

(18 August 2022):  Radiopharmaceutical company Cyclopharm Limited (ASX:CYC) has announced results for the six-months to the end of June.

(18 August 2022):  CSL has announced positive top-line results from a Phase 3 study of its investigational candidate garadacimab in patients with hereditary angioedema.

(16 August 2022):  Opthea (ASX:OPT) has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics to progress the development of OPT-302 for wet age-related macular degeneration.

(16 August 2022):  Cell therapy immuno-oncology company Carina Biotech has raised $7.5 million at the first close of its current funding round.

(16 August 2022):  Australian company Microbio says it has received clearance from UK authorities for the sale of its InfectID-BSI bloodstream infection test in the country.

(16 August 2022):  EpiAxis Therapeutics has announced a new collaboration with Peptilogics under which they will aim to leverage artificial intelligence for drug discovery to inhibit epigenetic oncology targets.

(9 August 2022):  Researchers at the National Vaccine and Therapeutics Lab work to develop vaccine and drug candidates into products that can be manufactured in large quantities for clinical trials.

(11 August 2022):  Therapeutic antibody development company Patrys (ASX:PAB) has announced new pre-clinical data for its lead asset, PAT-DX1, from a study conducted by Professor Terrence Johns of the Telethon Kids Cancer Centre.

(11 August 2022):  Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and characterisation.

(11 August 2022):  PolyNovo (ASX:PNV) has announced that the first patient has been enrolled in its trial evaluating the clinical safety and efficacy of its NovoSorb SynPath for the treatment of chronic diabetic foot ulcers.

(9 August 2022):  Neuren Pharmaceuticals (ASX:NEU) has announced its Phase 2 clinical trials of NNZ-2591 in children with each of Phelan-McDermid syndrome and Pitt Hopkins syndrome are open for enrolment.

(9 August 2022):  Telix (ASX:TLX) has announced that it has been jointly awarded a $4.8 million Australian Research Council grant to establish a new Industrial Transformation Research Program Hub as part of a consortium of applicants led by The University of Queensland.

(9 August 2022):  Dimerix (ASX:DXB) has announced a new patent family application for its lead investigative candidate DMX-700 for the treatment of Chronic Obstructive Pulmonary Disease.

(4 August 2022): Pfizer has significantly raised its offer for Australian digital health company ResApp Health (ASX:RAP) to a price that reflects the recent findings of an independent report.

(4 August 2022): Radiopharm Theranostics (ASX:RAD) has announced a collaboration agreement with Lantheus.

(2 August 2022):  Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials.

(2 August 2022):  Australian researchers are seeking volunteers aged 40 and over living with severe emphysema for a world-first study of a novel two-stage procedure to treat the lung disease.

(2 August 2022):  Proteomics International Laboratories (ASX:PIQ) has announced that a study demonstrating the clinical utility of the PromarkerD test in predicting diabetic kidney disease has been published in the journal PLOS ONE.

(28 July 2022):  The Clinical Translation and Commercialisation Medtech Program will open its second round in September 2022 seeking applications from small to medium-sized enterprises.

(28 July 2022):  Volpara Health Technologies (ASX:VHT) has announced the completion of the strategic review undertaken by CEO Teri Thomas and the executive management team.

(28 July 2022):  Molecular diagnostics company Genetic Signatures (ASX:GSS) has completed recruitment for the clinical trial of its 3base EasyScreen Enteric Protozoan Diagnostic Kit in the US.

(28 July 2022):  Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received feedback from the US FDA following a review of the Investigational New Drug application for a new oral therapeutic targeting Campylobacter and ETEC.

(26 July 2022):  The global research-based biopharmaceutical industry has launched its own response to the World Trade Organization's recent waiver of intellectual property protection for COVID-19 vaccines and treatments.

(26 July 2022):  Medical software technology company ImpediMed (ASX:IPD) has announced the departure of its managing director and CEO Richard Carreon.

(26 July 2022):  Adherium (ASX: ADR) has announced that it has received US FDA clearance to market application connecting GSK’s Ellipta inhaler users with its new Hailie sensor with physiological parameters for monitoring Asthma and COPD medication use.

(26 July 2022):  Amplia Therapeutics (ASX:ATX) has announced that an abstract describing its ACCENT clinical trial of AMP945 in first-line patients with advanced pancreatic cancer has been accepted for presentation at the American Association for Cancer Research Special Conference on Pancreatic Cancer.

(21 July 2022):  A major milestone for Australian company Neuren Pharmaceuticals (ASX:NEU) with its US partner Acadia submitting trofinetide to the FDA for the treatment of Rett syndrome.

(21 July 2022):  Australia’s national biotechnology incubator CUREator has announced over $17 million in funding for 23 projects across six states and territories.

(21 July 2022):  Australian digital health company ResApp Health (ASX:RAP) is urging shareholders to support Pfizer's acquisition of the company after the competition regulator confirmed it will not review the proposal.

(19 July 2022):  AuBiotech CEO Lorraine Chiroiu says the sector is very concerned by the decision to waive IP protection for COVID-19 vaccines and treatments given what it says about the lack of understanding of its importance to attracting investment that ultimately supports innovation.

(19 July 2022):  Rhinomed (ASX:RNO) has finalised a supply agreement with SureScreen to supply Rhinoswabs and Rhinoswab Juniors for inclusion in SureScreen’s range of lateral flow point of care test kits in the Australian, New Zealand, Singapore and South Pacific markets.

(19 July 2022):  Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Mike Tonroe as its chief financial officer.

(12 July 2022):  Neuren Pharmaceuticals (ASX:NEU) has announced that its Phase 2 clinical trial of NNZ-2591 in Angelman syndrome (AS) is open for enrolment.

(14 July 2022):  Cell therapy company Cynata Therapeutics (ASX:CYP) has secured a US patent covering the use of its Cymerus mesenchymal stem cell technology in treating asthma and allergic airways disease.

(14 July 2022):  Actinogen Medical (ASX:ACW) has provided further information on the timing and design of its upcoming biomarker study in patients with mild Alzheimer’s disease.

(12 July 2022): Emerging Australian company Recce Pharmaceuticals (ASX:RCE) has appointed an experienced industry executive to lead the translation of its pipeline of anti-infectives.

(12 July 2022): Telix Pharmaceuticals (ASX:TLX) has announced the appointment of a CEO for its Americas business and dosed the final patient and completed recruitment into the pivotal Phase 3 study, ZIRCON.

(12 July 2022): New Australian research has identified child cancer patients at the greatest risk of developing life-threatening infections.

(12 July 2022):  NeuroScientific Biopharmaceuticals (ASX:NSB) says it has submitted an application for Human Research Ethics Committee approval to commence a Phase I clinical trial of its lead drug candidate EmtinB.

(7 July 2022):  A new Australian study has identified what may be a critical factor in the development of Alzheimer’s disease.

(7 July 2022):  Patrys (ASX:PAB) has announced that its contract development manufacturing organisation has successfully completed a second engineering run that used an updated purification process to produce large-scale quantities of clinical-grade PAT-DX1.

(7 July 2022):  Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced the timing of the submission of the NDA for Sofpironium Bromide has been accelerated.

(7 July 2022): Digital health company ResApp Health (ASX:RAP) has agreed to a 12-month extension to its commercial licence agreement with Medgate.

(5 July 2022):  Australian researchers have identified a new drug target for the treatment and prevention of chronic obstructive pulmonary disease.

(5 July 2022):  Biotech incubator CUREator will receive $3 million in funding from CSIRO to support Australia’s health security and protect against emerging infectious diseases and pandemics.

(5 July 2022): Dimerix (ASX:DXB) has announced new data showing the efficacy of its pipeline program, DMX-700, in an industry-standard preclinical model of chronic obstructive pulmonary disease.

(30 June 2022): NeuroScientific Biopharmaceuticals (ASX:NSB) has announced the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB.

(30 June 2022): Asia Pacific-based Novotech, which recently expanded its services to the US, has been awarded the Best Biologics CRO Award.

(30 June 2022): Starpharma (ASX:SPL) has announced that VIRALEZE nasal spray has been relaunched by LloydsPharmacy in the UK.

(28 June 2022): Regenerative medicine company Orthocell (ASX:OCC) has entered into an exclusive patent and trademark license agreement and an exclusive distribution and supply agreement with BioHorizons Implant Systems.

(28 June 2022): Starpharma (ASX:SPL) has signed an expanded DEP research agreement with Genentech, a member of the Roche Group, to evaluate additional DEP drug conjugates.

(28 June 2022): Lumos Diagnostics (ASX:LDX) has announced it has received Interim Order authorisation from Health Canada for its ViraDx three-in-one rapid antigen test for COVID-19, Flu A and Flu B.

(23 June 2022): The Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Medical Research a grant of $1.45 million to fund the joint development program of novel anti-inflammatory compounds.

(23 June 2022): Volpara Health Technologies (ASX:VHT) has announced a new research and development collaboration with Microsoft to accelerate the creation of a product that detects and quantifies breast arterial calcifications.

(21 June 2022): The research-based life sciences industry says the decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have a negative impact on future innovation.

(21 June 2022): Kazia Therapeutics (ASX:KZA) has announced that the US FDA has granted Orphan Drug Designation to its paxalisib for the treatment of atypical rhabdoid/teratoid tumours.

(16 June 2022): Australian life sciences company ResMed (ASX:RMD) has announced the US$1 billion acquisition of German software company MEDIFOX DAN.

(16 June 2022): NeuroScientific Biopharmaceuticals (ASX:NSB) has announced positive preliminary results of lead drug candidate EmtinB in an animal model of Multiple sclerosis.

(14 June 2022): EpiAxis Therapeutics has announced the results of its clinical trial EPI-PRIMED - the first time that an epigenetic inhibitor has been used in combination with chemotherapy to treat metastatic cancer.

(14 June 2022): Telix Pharmaceuticals (ASX:TLX) and US-based RefleXion Medical have signed a new co-development and commercialisation agreement.

(14 June 2022): Regenerative medicine company Regeneus (ASX:RGS) has announced that its CEO Karolis Rosickas has purchased over 3.8 million shares in the company.

(9 June 2022): Telix Pharmaceuticals (ASX:TLX) has received a $17.25 million R&D tax refund from the federal government for eligible activities undertaken in the year ended 31 December 2021.

(9 June 2022): Dimerix (ASX:DXB) has entered into an agreement with The Australian Centre for Accelerating Diabetes Innovations to progress its DMX-200 into a new clinical trial in patients with diabetic kidney disease.

(9 June 2022): Researchers have developed a new blood test that could revolutionise how chemotherapy is used for colon cancer by identifying the patients that need chemo and those that can be safely spared treatment.

(7 June 2022):  For the first time in more than two years, a number of Australian biotechnology companies are in the US for one of the world's most important oncology events – the global conference of the American Society of Clinical Oncology.

(7 June 2022):  Clarity Pharmaceuticals (ASX:CU6) has announced the approval of its IND application by the US FDA to evaluate its SAR Bombesin product as an imaging agent in prostate cancer patients that are PSMA-negative.

(7 June 2022):  Immutep (ASX:IMM) has released new data from the phase 2 lung cancer trial evaluating its lead product candidate eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients.

(2 June 2022): Cell therapy immuno-oncology company Carina Biotech has appointed Australian organisation Cell Therapies to undertake Good Manufacturing Processes manufacture of its LGR5 CAR-T cells for a first-in-human clinical trial.

(2 June 2022): Dimerix (ASX:DXB) has announced the recruitment of the first patient to its DMX-200 phase 3 trial in patients with FSGS kidney disease.

(2 June 2022): Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of surgical oncologist Dr Yanghee Woo to its scientific advisory board.

(31 May 2022): Channel Bio recently launched its new state-of-the-art facility at The Grounds of Alexandria in Sydney.

(31 May 2022): Australian cell therapy company Cynata Therapeutics (ASX:CYP) has announced that St George Hospital in Sydney is now a participating site and is seeking to recruit patients in the MEND clinical trial.

(31 May 2022): Respiratory eHealth company Adherium (ASX:ADR) has announced the appointment of Tara Creaven-Capasso as its vice president of quality, regulatory and clinical affairs.

(26 May 2022): Brandon Capital has partnered with another investor to inject NZ$15.25 million into the University of Auckland spin-out TamoRx.

(26 May 2022): PharmAust (ASX:PAA) is launching a Phase 1 clinical trial of monepantel for the treatment of motor neuron disease or Amyotrophic Lateral Sclerosis.

(26 May 2022): Archer Materials (ASX:AXE) has secured an Australian patent for its 12CQ quantum computing chip technology.

(14 May 2022): Living Cell Technologies (ASX:LCT) says artificial intelligence will be applied to its research into Parkinson’s disease under a new agreement with OptiCellAI.

(19 May 2022):  Immutep (ASX:IMM) has announced the appointment of four new members to its Clinical Advisory Board.

(19 May 2022):  Starpharma (ASX:SPL) says SPL7013, the antiviral agent in VIRALEZE nasal spray, achieved 95 per cent and 99.7 per cent reduction in viral infectivity against two significant types of influenza virus, A and B, respectively, in virucidal assays.

(19 May 2022):  AnteoTech (ASX:ADO) has registered an updated EuGeni COVID-19 Rapid Antigen Test in Europe under the In Vitro Diagnostic Directive 98/79/EC Regulations.

(19 May 2022):  Medibio (ASX:MEB) has announced that a DSM-V 1 diagnosis will be included as a primary comparator for the purposes of assessing the efficacy of its depression algorithms, MEB-001.

(17 May 2022):  Illumina's global chief commercial officer Susan Tousi believes genomics will be a significant factor in the accelerated development of targeted therapies.

(17 May 2022):  Nyrada (ASX:NYR) says the European Patent Office has issued a Notice of Intention to grant the company’s patent application number EP18768188.7.

(12 May 2022):  ENA Respiratory says it has been selected to join a major joint initiative between Johnson & Johnson Innovation - JLABS and the US government's Biomedical Advanced Research and Development Authority.

(12 May 2022):  Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has submitted an Investigational New Drug application to the US FDA for a new oral therapeutic targeting Campylobacter and ETEC.

(12 May 2022):  NeuroScientific Biopharmaceuticals (ASX:NSB) has submitted an application seeking approval for an early-phase clinical trial involving its lead drug candidate EmtinB.

(10 May 2022):  Dimerix (ASX:DXB) has received approval from the US FDA to proceed with the Phase 3 study of DMX-200 in patients with focal segmental glomerulosclerosis.

(10 May 2022):  Immuno-oncology company Imugene (ASX:IMU) has announced it has received Human Research Ethics Committee approval to commence a Phase 2 clinical trial of its immunotherapy candidate, HER-Vaxx in Australia.

(10 May 2022):  Prescient Therapeutics (ASX:PTX) has announced the expansion of its Phase 1b clinical study of PTX-200 and cytarabine in patients with relapsed and refractory acute myeloid leukemia.

(5 May 2022):  Australian biotechnology company Tessara Therapeutics has announced a series of advisory board appointments. 

(5 May 2022):  Botanix Pharmaceuticals (ASX:BOT) has announced the acquisition of a novel dermatology asset known as Sofpironium Bromide gel.

(3 May 2022):  Biotron (ASX:BIT) has announced its lead clinical drug BIT225 has demonstrated effective protection from severe disease in mice with established SARS-CoV-2 infection in a new animal study performed at The SCRIPPS Research Institute in the US. 

(3 May 2022):  Inoviq (ASX:IIQ) says it has executed an agreement with MP Biomedicals for the contract manufacture of its proprietary SubB2M protein.

(28 April 2022):  Cochlear has announced it will acquire Oticon Medical for $170 million following Demant’s decision to exit its hearing implants business activities.

(28 April 2022):  Paradigm Biopharmaceuticals (ASX:PAR) says the first subjects have been randomised and dosed in the US in the PARA_OA_002 pivotal clinical trial.

(26 April 2022):  Opthea (ASX:OPT) has announced the appointment of Quinton Oswald and Dr Susan Orr to its board of directors.

(21 April 2022):  Arovella Therapeutics (ASX:ALA) has announced it has agreed commercial terms for the initial manufacturing services agreement for its first investigative CAR19-iNKT cell therapy candidate with Q-Gen Cell Therapeutics.

(21 April 2022):  Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced that its phase 2 study of paxalisib in glioblastoma (NCT03522298) has been successfully completed.

(21 April 2022):  Medlab Clinical (ASX:MDC) has announced a northern hemisphere trade deal with the former contract manufacturer of NRGBiotic.

(21 April 2022):  Volpara Health Technologies (ASX:VHT) has announced changes to its board and leadership team in a move it says is designed to support its next phase of growth.

(19 April 2022):  A skin microbiopsy device developed by researchers at The University of Queensland could change the way skin cancers and other skin conditions are diagnosed and monitored.

(19 April 2022):  EpiAxis Therapeutics has announced biomedical scientist, Dr Darren Saunders, as its new chief science officer.

(19 April 2022):  Zelira Therapeutics (ASX:ZLD) has announced it has executed a binding scheme implementation deed under which it proposes to acquire 100 per cent of Health House.

(14 April 2022):  NeuroScientific Biopharmaceuticals (ASX:NSB) has reported positive outcomes from its preclinical safety and toxicology program involving its lead drug candidate EmtinB.

(14 April 2022):  Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has confirmed upcoming presentations of data related to its antimicrobial synthetic cannabidiol program BTX 1801.

(14 April 2022):  Clinical stage immuno-oncology company Imugene (ASX:IMU) says City of Hope in the US has dosed the first cohort two patient in the Phase I clinical trial of the company's oncolytic virotherapy candidate.

(12 April 2022):  Pfizer has announced it will acquire ResApp Health (ASX:RAP) in an acquisition that values the Australian digital health company at $100 million.

(12 April 2022):  Microbio expects said it expects clinical evaluation trials of its InfectID-BSI tests to be completed next month, prior to launching in the European market.

(12 April 2022):  Rhinomed (ASX: RNO) has successfully completed the institutional component of the partially underwritten accelerated non-renounceable entitlement offer and raised approximately $3.37 million.

(7 April 2022):  Dr Kurt Sales has extensive experience in applied and academic research, preclinical drug development, clinical study support, and business development and management.

(7 April 2022):  Two major new projects for MTPConnect with the organisation announcing new partnerships with  Pathology Technology Australia and DMTC.

(7 April 2022):  Race Oncology (ASX:RAC) has received human ethics approval for its open-label clinical trial of Zantrene in patients with extramedullary Acute Myeloid Leukaemia or high-risk Myelodysplastic Syndrome.

(5 April 2022): A leading Australian healthcare investor is urging their counterparts and governments to give greater backing to the country's medical research sector.

(31 March 2022): Living Cell Technologies (ASX:LCT) says it has advanced plans for a third clinical trial of NTCELL in Parkinson’s disease.

(31 March 2022): Avecho Biotechnology (ASX:AVE) has announced positive results for its Phase 2a study examining the effects of its topically applied CBD formulation on the symptoms of osteoarthritis.

(29 March 2022):  Clinical stage biotechnology company Hexima (ASX:HXL) has announced its chief operating officer Dr Nicole van der Weerden presented data on its compound pezadeftide to the annual meeting of the American Academy of Dermatology.

(29 March 2022):  Dimerix (ASX:DXB) has announced it has received an R&D Tax Incentive rebate of $3.695 million for the 2020-21 year.

(29 March 2022):  Neuren Pharmaceuticals (ASX:NEU) has received US FDA approval to proceed with the Phase 2 trial of NNZ-2591 in Pitt Hopkins syndrome.

(24 March 2022):  BioScience Managers has welcomed the US FDA’s approval of Saluda Medical’s Evoke Spinal Cord Stimulation System.

(24 March 2022):  Agilex Biolabs has launched its new laboratory for the analysis of large molecule therapeutics, more than doubling the geographic area of its Adelaide campus.

(22 March 2022):  Managing director Paul Anderson said, “Remplir is the first of its kind biological scaffold designed by an Australian team of researchers to mimic the outer layer of the peripheral nerve and facilitate high-quality nerve repair."

(22 March 2022):  Noxopharm (ASX:NOX) has announced that its lead oncology drug candidate Veyonda has been granted Orphan Drug Designation by the US FDA for its use in the treatment of soft tissue sarcoma.

(22 March 2022):  Biotron (ASX:BIT) says its lead clinical asset BIT225 has again demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal studies performed at The SCRIPPS Research Institute in the US.

(17 March 2022):  ENA Respiratory (ASK:ENA) has announced it has dosed the first participants in a Phase 2a flu-challenge study of its INNA-051.

(17 March 2022):  Paradigm Biopharmaceuticals (ASX:PAR) has announced it has received regulatory and ethics approval from the UK regulator for a key late-stage clinical trial.

(15 March 2022): Neuren Pharmaceuticals (ASX:NEU) has announced it has received approval from the Human Research Ethics Committee for its Phase 2 clinical trial of NNZ-2591 in Angelman syndrome.

(10 March 2022): Telix (ASX:TLX) has announced that its ZIRCON Phase 3 study of investigational kidney cancer imaging agent, TLX250-CDx, has dosed the target enrolment of 252 patients.

(10 March 2022): A new name for the largest life science investment fund in Australia in New Zealand with the Medical Research Commercialisation Fund rebranded Brandon BioCatalyst.

(8 March 2022): Recognition for Vetter with the contract development and manufacturing organisation recognised at the 2022 CMO Leadership Awards.

(8 March 2022): Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has announced the results of the phase 1 clinical trial of its CORE NK platform.

(3 March 2022): Starpharma (ASX:SPL) has announced that its Australian developed VIRALEZE antiviral nasal spray achieved the maximum possible virucidal effect against the highly transmissible Omicron variant of SARS-CoV-2.

(3 March 2022): Antisense Therapeutics (ASX:ANP) has announced that new data on ATL1102 in Duchenne muscular dystrophy will be presented in a poster presentation at a leading conference in the US.

(1 March 2022): Ms Turnbull rejoins Immutep’s board having previously served as its chair from October 2010 to November 2017.

(1 March 2022): Therapeutic antibody development company Patrys (ASX:PAB) has identified and selected an optimised stable cell line for the production of its full-sized IgG deoxymab, PAT-DX3.

(1 March 2022):  Neuren Pharmaceuticals (ASX:NEU) says it has received approval from the US FDA to proceed with the Phase 2 trial of NNZ-2591 in Angelman syndrome.

(24 February 2022): Kazia Therapeutics says it had $15.2 million in cash at the end of December 2021 having committed $11.4 million during the period to progress its pipeline.

(22 February 2022): Arovella Therapeutics (ASX:ALA) says its previously announced share purchase plan has been over-subscribed.

(17 February 2022): Amplia (ASX:ATX) has reported the publication of a key paper in the peer-reviewed journal Science Advances that shows pre-treatment with a FAK inhibitor improves the effectiveness of chemotherapy in a preclinical model of pancreatic cancer.

(15 February 2022): The executive of the Agricultural Biotechnology Council of Australia has announced the appointment of Dr Joe Smith as its new chair. 

(15 February 2022): Adelaide-based COVID vaccine developer Sementis has appointed Dr Anne Collins as its chief operating officer.

(10 February 2022): Tessara Therapeutics has announced a series of senior appointments as it works to bring its RealBrain technology to market.

(10 February 2022): A new survey commissioned by CSL has revealed more than four in five Australians think medical research is vitally important to the country's future.

(8 February 2022): NeuroScientific Biopharmaceuticals (ASX:NSB) has reported outcomes from recently completed in vitro genotoxicity studies and plasma protein binding studies involving its lead drug candidate EmtinB.

(8 February 2022): Medlab Clinical (ASX:MDC) says it has received 'Favourable Opinion' status from the UK Research Ethics Committee for the forthcoming NanaBis Phase 3 trial.

(3 February 2022): The federal government has announced a $2.2 billion University Research Commercialisation Action Plan designed to put university innovation and industry collaboration front and centre of Australia’s economic recovery.

(3 February 2022): Cytiva said the competition attracted 32 proposals from academic institutions and start-up companies across the region’s biotechnology industry.

(1 February 2022): Exopharm (ASX:EX1) has signed a Master Collaborative Services Agreement with the Astellas Institute for Regenerative Medicine.

(1 February 2022): Australian company Pharmaxis (ASX:PXS) has announced that a phase 1c trial of its novel topical drug treatment has commenced dosing in patients with established scars. 

(27 January 2022): Telix Pharmaceuticals (ASX:TLX) has announced that the first patient has been dosed in its prostate-specific membrane antigen targeting ‘ProstACT’ therapeutic program.

(27 January 2022): A new partnership for BiomeBank with the clinical-stage microbiome therapeutics company announcing an agreement with Hudson Institute of Medical Research.

(25 January 2022): Telix Pharmaceuticals (ASX:TLX) has raised $175 million it says will be used to fund the progression of its promising pipeline.

(25 January 2022): Technovalia has announced the interim safety results of the ongoing phase 1 clinical trial evaluating COVIGEN, a DNA Covid-19 vaccine candidate, in healthy participants using the PharmaJet Needle-free Devices.

(20 January 2022): BiomeBank had announced the appointment of the former chief investment officer of Ellerston Capital as its new chair.

(18 January 2022): Pharmaxis (ASX:PXS) says it welcomes new drug development grants from the federal government awarding NHMRC funding to two research teams to advance work they are conducting with two of the company's discoveries.

(18 January 2022): Dimerix (ASX:DXB) says the first patients have been dosed in the India-based CLARITY 2.0 feasibility/Phase 3 study of DMX-200 as a potential new treatment for respiratory complications associated with COVID-19.

(16 December 2021): CSL Limited (ASX:CSL) has announced the successful completion of its $6.3 billion institutional placement with proceeds to support the company's acquisition of Vifor Pharma.

(16 December 2021):  A potential new treatment in development for multiple sclerosis created at QIMR Berghofer Medical Research Institute has secured a deal worth up to $63 million.

(14 December 2021): Starpharma (ASX:SPL) has signed a commercial arrangement for its antiviral nasal spray Viraleze in Vietnam with orders in excess of 2 million since late October.

(9 December 2021): Synthetic anti-infective company Recce Pharmaceuticals (ASX:RCE) has provided an update on its Phase I/II clinical trial for the treatment of burn wound infections.

(7 December 2021): University of Melbourne-led research has shown the flavonoid pinocembrin, derived from Australian eucalyptus trees, has strong anti-inflammatory properties.

(7 December 2021): Neuren Pharmaceuticals (ASX:NEU) has reported that its partner for trofinetide in North America, Acadia Pharmaceuticals, has announced positive top-line results from a Phase 3 study.

(2 December 2021): New research from St Vincent’s Institute of Medical Research on lipoedema could support the development of new treatments and the development of a diagnostic screening test.

(2 December 2021): Bionomics (ASX:BNO) has announced that the US FDA has granted Fast Track designation to the BNC210 development program for the acute treatment of Social Anxiety Disorder and other anxiety-related disorders.

(30 November 2021): Digital health company ResApp (ASX:RAP) has announced TGA clearance and CE Mark certification for its standalone cough counter smartphone application.

(30 November 2021):  The Victorian government says researchers in the state have produced Australia's first mRNA COVID-19 vaccine candidate.

(30 November 2021): BARD1 said it has signed an agreement with Griffith University to provide consultancy and scientific services to support the development and evaluation of an exosome-based RNA test for the detection of ovarian and breast cancers.

(25 November 2021): Biotron (ASX:BIT) has announced that its lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research Institute in the US.

(23 November 2021): The incubator will be located over two floors at CSL’s new global corporate headquarters that is currently under construction in the Melbourne Biomedical Precinct.

(16 November 2021): Telix Pharmaceuticals (ASX:TLX) has announced that the first  Australian patient has been dosed in the international NOBLE Registry.

(9 November 2021): Dr Chris Nave, the CEO and co-founder of the Medical Research Commercialisation Fund, said that while any funding is positive, the reality is that gaps remain access to adequate capital for the translation of Australian biotechnology.

(11 November 2021): Australian start-up medical device company Nirtek is one of seven companies awarded funding through the federal government's TTRA initiative.

(9 November 2021): University of Queensland research shows bacteria found in children’s upper respiratory systems could help fight chronic middle ear infections.

(4 November 2021): The TGA has approved Telix Pharmaceuticals' (ASX:TLX) lead prostate cancer imaging product, Illuccix (TLX591-CDx).

(2 November 2021): Biotron (ASX:BIT) has commenced two clinical trials with its lead antiviral drug BIT225 in HIV-1-positive populations.

(2 November 2021): Antisense Therapeutics (ASX:ANP) has announced positive news from the Paediatric Committee of the European Medicines Agency and the successful completion of a capital raise.

(28 October 2021): Wearable nasal and respiratory technology company Rhinomed (ASX:RNO) says it is continuing to generate data that supports the Rhinoswab as the preferred sampling method for the diagnosis of upper respiratory disease.

(26 October 2021): Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced the successful completion of the manufacturing for CHM 2101 research-grade plasmids.

(26 October 2021): Noxopharm (ASX:NOX) has received Notices of Allowance from patent offices in Australia and Europe covering the use of idronoxil (the active ingredient in Veyonda) as a chemo-enhancing drug.

(21 October 2021): The fully subscribed capital raising was managed by Henslow and the company said it will use the funds to build its organisation and progress its technology development program.

(21 October 2021): Australian businesses have been incited to participate in the newly launched Medtronic APAC Innovation Challenge.

(14 October 2021): Microbio has moved into new laboratories at Brisbane’s Translational Research Institute (TRI) with the aim of eventually setting up domestic manufacturing capability.

(19 October 2021): Dimerix is partnering with the NHMRC Clinical Trials Centre at the University of Sydney to expand a feasibility/phase 3 trial of its DMX-200 drug candidate to treat COVID-19 sufferers with respiratory complications.

(14 October 2021): IDT has announced a new agreement with Monash University under which it will provide contract manufacturing services to the Monash Institute of Pharmaceutical Sciences for its mRNA COVID-19 vaccine clinical trial. 

(28 September 2021): Clinical-stage drug development company Dimerix (ASX:DXB) has announced that the Indian regulator has formally recommended the approval of the study of DMX-200 in patients with COVID-19.

(28 September 2021): Cell therapy company Cynata Therapeutics (ASX:CYP) has announced that a scientific paper describing the use of its Cymerus mesenchymal stem cells in a model of myocardial infarction has been published in the peer-reviewed journal Cytotherapy.

(23 September 2021): Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced it has received a notice of grant from the Japanese Patent Office for its application to protect its HER-Vaxx immunotherapy.

(23 September 2021): Experts have released research that says drug repurposing is no quick fix for developing new treatments for COVID-19 with inherent dangers and pitfalls in translating drugs to treat the virus.

(21 September 2021): Certa Therapeutics has announced the launch of a Phase 2 trial in Australia for a potential new treatment for Diffuse Systemic Scleroderma.

(21 September 2021): Clinical-stage biopharmaceutical company Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute Social Anxiety Disorder.

(16 September 2021): Australian company Microbio has announced that its COVID-19 tests have been approved for sale and use in Europe.

(14 September 2021): Wearable nasal and respiratory technology company Rhinomed (ASX:RNO) has received an initial purchase order for one million Rhinoswabs from the Victorian Department of Health to support the state's testing capability.

(9 September 2021): WEHI and global biopharmaceutical company MSD have established a three-year exchange program whereby researchers can be seconded to the company's Research Laboratories in South San Francisco.

(9 September 2021): Telix Pharmaceuticals (ASX:TLX) has announced that the last patient has been imaged in a phase one clinical study of the company's investigational prostate cancer imaging product TLX591-CDx.

(7 September 2021): Regenerative medicine company Orthocell (ASX:OCC) has announced that new patents have been granted in Canada and Hong Kong for its novel CelGro collagen medical device platform for soft tissue regeneration applications.

(2 September 2021): Neuren Pharmaceuticals (ASX:NEU) today reported that its US partner for trofinetide, Acadia Pharmaceuticals, will be conducting a clinical trial in girls with diagnosed Rett syndrome.

(31 August 2021): Pharmaxis (ASX:PXS) has announced that its novel topical drug treatment for scarring has delivered positive phase one clinical trial results and will now advance to the next stage of development in patients

(27 August 2021): Microba Life Sciences will work with Anatara Life Sciences (ASX:ANR) to complete microbiome analysis for a therapeutic treatment for sufferers of IBS-D.

(26 August 2021): A new report from CSIRO says Australia could develop an industry worth up to $27 billion a year and create 44,000 jobs by 2040 by building its synthetic biology ecosystem.

(24 August 2021): AdAlta (ASX:1AD) and Carina Biotech have announced a collaboration agreement to develop next-generation i-body enabled CAR-T cells.

(24 August 2021): Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the US FDA has cleared an Investigational New Drug application for CHM 1101 for patients with recurrent or relapsed Glioblastoma.

(19 August 2021): Telix Pharmaceuticals (ASX:TLX) has announced new collaborations and studies of its investigational technologies.

(17 August 2021): The TGA has approved the COVID-19 diagnostic test developed by the Australian company SpeeDx.

(17 August 2021): Clinical-stage biopharmaceutical company Dimerix (ASX:DXB) has announced a $20 million capital raise via a two-tranche placement of approximately 100 million new shares.

(17 August 2021): The Brandon Capital managed Medical Research Commercialisation Fund has received funding to nationally roll out the Women in Leadership Development program.

(12 August 2021): Rhinomed (ASX:RNO), a company working on wearable nasal and respiratory technology, says it has received purchase orders and begun supplying NSW Health Pathology with an initial one million Rhinoswabs.

(12 August 2021): Proteomics International Laboratories (ASX:PIQ) has announced it has contracted French immunoassay specialist Biotem to manufacture test kits for the PromarkerD predictive test for diabetic kidney disease.

(10 August 2021): Clinical-stage drug development company Noxopharm (ASX:NOX) has announced a formal collaboration with the National Cancer Institute within the US National Institutes of Health in the quest for more effective treatments of brain cancer.

(10 August 2021): Clinical stage biopharmaceutical company Opthea (ASX:OPT) has announced that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet age-related macular degeneration.

(5 August 2021): Neuren Pharmaceuticals (ASX: NEU) today announced that its US partner Acadia Pharmaceuticals has successfully completed enrolment in the LAVENDER Phase 3 trial of trofinetide in Rett syndrome.

(5 August 2021): Immutep (ASX:IMM) has announced that the first patient has been enrolled and safely dosed in INSIGHT-003 study that includes its LAG-3 investigative immunotherapy.

(3 August  2021): Dimerix (ASX:DXB) has announced that 167 patients have now been recruited into the feasibility/Phase 3 ACE2 renin-angiotensin system modulation study domain in patients with COVID-19 pneumonia that incorporates DMX-200.

(3 August 2021): Faecal transplants are the latest new treatment option being trialled in people living with Parkinson’s to help manage their symptoms by replenishing their healthy gut bacteria. 

(3 August 2021): Bionomics (ASX:BNO) has announced that it plans to conduct a registered initial public offering of shares in the US and a listing on Nasdaq.

(29 July 2021): Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has entered into an exclusive licensing agreement with the University of Pennsylvania for the CDH17 chimeric antigen receptor T cell therapy.

(27 July 2021):  Australian biotech company CTxONE Pty has re-branded to Oncology One in a move it says will support its goal to raise and deploy meaningful capital to progress small molecule cancer drug discovery projects towards the clinic.

(27 July 2021): Patrys (ASX:PAB) says new preclinical data from the Garvan Institute of Medical Research has shown that its’ deoxymab antibody PAT-DX1 is able to slow tumour growth and increase survival in an animal model of pancreatic cancer.

(20 July 2021): Johnson & Johnson Innovation has announced the extension of its partnering office at Monash University's Clayton Campus (JJIPO@Monash) in Melbourne in collaboration with the Victorian government.

(15 July 2021): Australian company Planet Innovation has opened a new cleanroom at their facility in the Melbourne suburb of Box Hill.

(13 July 2021): The University of Queensland's technology transfer company UniQuest has announced a new partnership with CSL to develop a potential treatment for the repair of blood vessels damaged by inflammation.

(13 July 2021): Therapeutic antibody development company Patrys (ASX:PAB) has announced new data from non-clinical studies have confirmed its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross the blood-brain barrier in an animal model of primary brain cancer.

(6 July 2021): Opthea (ASX:OPT) has announced that the US FDA has granted Fast Track designation for its OPT-302 in combination with anti-VEGFA therapy for the treatment of patients with neovascular age-related macular degeneration.

(6 July 2021): Tessara Therapeutics has announced a collaboration with the Florey Institute of Neuroscience and Mental Health under which they will develop tissue therapies for the treatment of neurological diseases.

(6 July 2021): Digital health company ResApp Health (ASX:RAP) has announced the publication of acute exacerbation of COPD data from its Breathe Easy adult clinical study and a new commercial agreement with Australian-based telehealth company Doctors on Demand.

(1 July 2021): Australian company SpeeDx and MolGen have announced an agreement to collaborate on the supply and distribution of clinical diagnostics products and instrumentation across Europe and the Asia Pacific.

(1 July 2021): The company behind Australia’s first facility for the manufacturing of microbial therapies has applied to the Therapeutic Goods Administration for approval of their world-first biologic drug product.

(29 June 2021): QBiotics, a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, has announced the completion of an $85 million capital raise.

(29 June 2021): Antisense Therapeutics (ASX:ANP) has announced a new R&D collaboration with researchers at the Murdoch Children’s Research Institute’s to further investigate the potential of its ATL1102.

(24 June 2021): Opal Biosciences has called for expressions of interest from companies and organisations wishing to support and/or participate in the formation of a Victorian Life Sciences and Biotechnology Development and Manufacturing Precinct.

BiotechDispatch (22 June 2021): Pfizer’s Centers for Therapeutic Innovation has entered a new oncology-focused research collaboration with the Melbourne-based St Vincent’s Institute of Medical Research.

BiotechDispatch (22 June 2021): SUDA Pharmaceuticals (ASX:SUD) has announced it has signed a global, exclusive agreement with Imperial College London for a novel invariant Natural Killer T cell therapy platform.

BiotechDispatch (17 June 2021):  Regenerative medicine company Orthocell (ASX:OCC) has announced Chinese and New Zealand patents have been granted for its CelGro collagen medical device platform for soft tissue regeneration applications.

BiotechDispatch (15 June 2021): Starpharma (ASX:SPL) has announced that its Australian developed anti-COVID nasal spray Viraleze is now registered for use in India.

BiotechDispatch (10 June 2021): Proteomics International Laboratories (ASX:PIQ) has announced the expansion of its executive team with the appointments of Vik Malik as its new chief commercialisation officer (CCO) and Jacqueline Gray as its new chief financial officer.

BiotechDispatch (3 June 2021): Advanced Nuclear Medicine Ingredients, a wholly-owned European subsidiary of Telix, and Alpha Therapy Solutions have been jointly awarded a €990,000 ($1.56 million) ‘Eurostars-2’ research grant from the EUREKA Association.

BiotechDispatch (3 June 2021): QBiotics Group has dosed the first patient in the Phase Ib/IIa clinical trial of its lead oncology molecule, tigilanol tiglate, in combination with MSD’s immune checkpoint inhibitor KEYTRUDA (pembrolizumab).

BiotechDispatch (1 June 2021): Neuren Pharmaceuticals (ASX:NEU) says it has received "clear and constructive guidance" from the US FDA Office of Neuroscience in pre-IND meetings for Phase 2 clinical trials of NNZ-2591.

BiotechDispatch (1 June 2021): Testing by the Scripps Research Institute has found Starpharma's (ASX:SPL) Viraleze anti-COVID nasal spray is active against the highly infectious UK variant of SARS-CoV-2, the virus that causes COVID-19.

BiotechDispatch (27 May 2021): Regenerative medicine company Orthocell (ASX:OCC) has announced Chinese and Hong Kong patents have been granted for its novel CelGro collagen rope device, to augment the surgical repair of anterior cruciate ligament injuries.

BiotechDispatch (26 May 2021): Chimeric Therapeutics (ASX:CHM) has announced the treatment of the first patient in the second dose cohort in City of Hope’s phase 1 clinical trial evaluating the safety and tolerability of its chlorotoxin CAR T cell therapy.

BiotechDispatch (25 May 2021): Microba Life Sciences says it has united with Illumina to advance understanding of the human gut microbiome in human health and disease.

BiotechDispatch (20 May 2021): Recce Pharmaceuticals (ASX:RCE), a company developing new classes of synthetic anti-infectives, has announced further results for its R327.

BiotechDispatch (18 May 2021):  BioCurate and Monash University have announced the launch of Pio Therapeutics - a new company that will focus on developing novel, innovative and targeted medicines to improve outcomes for cancer patients.

BiotechDispatch (18 May 2021): Sanofi and GSK have announced they will advance their two-shot adjuvanted recombinant COVID-19 vaccine to a phase three clinical trial.

BiotechDispatch (11 May 2021): Telix Pharmaceuticals (ASX:TLX) says it has been granted HREC approval and received CTN clearance by the TGA for a phase 3 clinical trial of its PSMA targeted prostate cancer therapy candidate TLX591 (177Lu-DOTA-rosopatamab).

BiotechDispatch (13 May 2021): The company said the expanded facility is expected to create approximately 80 new advanced manufacturing jobs, in addition to jobs created due to construction.

BiotechDispatch (11 May 2021): Prescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne to advance its CAR-T programs utilising the OmniCAR platform.

BiotechDispatch (11 May 2021): Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute treatment of Social Anxiety Disorder while progressing toward the start of its planned Phase 2b trial in Post-Traumatic Stress Disorder.

BiotechDispatch (6 May 2021): Australian preclinical drug development company Nyrada (ASX:NYR) has provided an update on the progress of its small molecule cholesterol-lowering program. 

BiotechDispatch (4 May 2021): Recce Pharmaceuticals (ASX:RCE) has announced that its RECCE 327 has demonstrated bactericidal activity against all six antibiotic-resistant ESKAPE pathogens, including drug-resistant mutations as well as two additional WHO priority pathogens list.

BiotechDispatch (4 May 2021): A drug candidate discovered by the Australian company Pharmaxis (ASX:PXS) will be the focus of a new trial aimed at studying its potential as a treatment for an aggressive and deadly form of brain cancer.

BiotechDispatch (29 April 2021): The collaborative research aims to create a new generation of microbial therapies that can replace donor-derived faecal microbiota transplantation.

BiotechDispatch (29 April 2021):  Regenerative medicine company Orthocell (ASX:OCC) has announced what it describes as positive results from the US animal pilot study of its CelGro in nerve regeneration compared to the current market-leading device.

BiotechDispatch (27 April 2021): Telix Pharmaceuticals (ASX:TLX) has announced an agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development programs.

BiotechDispatch (22 April 2021): Kazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and a master services agreement with European company Evotec SE for EVT801, a small molecule, first-in-class oncology drug candidate.

BiotechDispatch (20 April 2021): An Australian consultancy has merged with an international equivalent in a move it says could open the way for Australian life science companies to access broader global markets.

BiotechDispatch (20 April 2021): Exopharm (ASX:EX1) says it has received 'firm commitments' from institutional and sophisticated investors for 16,666,667 shares to raise a total of $12 million in a placement.

BiotechDispatch (15 April 2021): Amplia Therapeutics (ASX:ATX), a company developing new drugs for the treatment for cancer and fibrosis, has announced it has successfully completed the dosing of subjects in its phase one clinical trial of its focal adhesion kinase inhibitor AMP945.

BiotechDispatch (15 April 2021): Australian company Pharmaxis has sold Russian distribution rights to cystic fibrosis therapy BRONCHITOL (mannitol) and completed a $4.4 million placement to institutional investors.

BiotechDispatch (13 April 2021): The consortium has announced they have received ethics approval for an Australian phase one clinical trial of the COVIGEN COVID-19 vaccine candidate.

BiotechDispatch (13 April 2021): AnteoTech (ASX:ADO) has announced it has received CE Mark registration for its EuGeni Reader and the in vitro rapid diagnostic test for the detection of SARS-CoV-2 nucleocapsid antigen, the COVID-19 ART.

BiotechDispatch (13 April 2021): An international research team led by Monash University has uncovered a new technique it says could speed up recovery from bone replacements by altering the shape and nucleus of individual stem cells.

BiotechDispatch (8 April 2021): Recce Pharmaceuticals (ASX:RCE) has announced that a SAS Category A notification has been made to the TGA by a medical practitioner following the successful treatment of a patient with RECCE 327.

BiotechDispatch (6 April 2021): Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced the lodgement of an international patent application aimed at protecting the use of Veyonda (idronoxil) in blocking the development of septic shock associated with infections.

BiotechDispatch (1 April 2021): Pharmaxis (PSX:ASX) has announced a partnership to launch a world-first clinical trial that aims to stop scars from forming after trauma, particularly following burn injuries.

BiotechDispatch (1 April 2021): Australian company Starpharma has announced that its antiviral nasal spray, Viraleze, which inactivates the coronavirus that causes COVID-19, has had its first commercial launch in the UK.

BiotechDispatch (30 March 2021): Pfizer brought together leaders in industry and the life sciences sector late last week for a roundtable to discuss the impact of COVID-19.

BiotechDispatch (23 March 2021): Preclinical Australian biotechnology company Nyrada (ASX:NYR) has announced it has received commitments to raise $11 million in capital it will use to support the development of its small molecule drugs to treat cardiovascular and neurological diseases.

BiotechDispatch (23 March 2021): The managing director of Novartis Oncology for Australia and New Zealand, Cheryl Maley, has been appointed to the board of Australian biotechnology company Medlab (ASX:MDC).

BiotechDispatch (16 March 2021): Immutep (ASX:IMM), an Australian biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, has announced a second clinical trial collaboration and supply agreement with MSD.

BiotechDispatch (16 March 2021): Emerging Australian biotechnology company Opthea (ASX:OPT) has announced that the first patient has been treated in the phase three pivotal clinical program of its first-in-class VEGF-C/D ‘trap’ inhibitor.

BiotechDispatch (11 March 2021): Neuren Pharmaceuticals (ASX:NEU) has announced that manufacturing of the drug substance for phase two trials of NNZ-2591 has been successfully completed on schedule.

BiotechDispatch (9 March 2021): Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that its lead investigational candidate Veyonda has been approved to move into its second and final stage of the NOXCOVID-1 clinical trial.

BiotechDispatch (9 March 2021):  Emerging Adelaide-based CAR-T therapy company Carina Biotech is led by three women who have made their careers in science commercialisation.

BiotechDispatch (4 March 2021): Regenerative medicine company Orthocell (ASX:OCC) has announced it has received notification from the Australian Department of Health that its CelGro Dental has been included on the Prostheses List.

BiotechDispatch (4 March 2021): Emerging Australia oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced a license agreement for its lead pipeline candidate Cantrixil (TRX-E-002-1).

BiotechDispatch (2 March 2021): Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has announced the initiation of a new study to investigate its Cymerus mesenchymal stem cells. 

BiotechDispatch (2 March 2021): Australian clinical-stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced the expansion of its management team with the appointment of three executives in the US.

BiotechDispatch (25 February 2021): Telix Pharmaceuticals (ASX.TLX) has announced that its Japanese subsidiary and partner Kanazawa University have received Clinical Trial Notification clearance to commence a phase one trial of its prostate cancer imaging product TLX591-CDx.

BiotechDispatch (25 February 2021): CSIRO has announced plans to develop new medicinal cannabis products designed to assist people with a variety of conditions including multiple sclerosis and chronic pain.

BiotechDispatch (25 February 2021): Cochlear, a global leader in implantable hearing solutions, has received US FDA clearance and CE Mark accreditation for the Baha 6 Max Sound Processor.

BiotechDispatch (23 February 2021): Australian pharmaceutical company Pharmaxis (ASX:PXS) has enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis

BiotechDispatch (23 February 2021): Starpharma (ASX:SPL) says it has received confirmation that the Viraleze antiviral nasal spray has been successfully registered for sale in Europe and the UK.

BiotechDispatch (16 February 2021): The TGA has approved Cell Therapies to commence the commercial production of Novartis' CAR-T cell therapy KYMRIAH at the Peter MacCallum Cancer Centre in Melbourne.

BiotechDispatch (16 February 2021): Australian biotechnology company Neuren Pharmaceuticals (ASX:NEU) has reported a phase one trial of its twice-daily oral investigative therapy NNZ-2591 found it was safe and well-tolerated for seven days.

BiotechDispatch (11 February 2021): Global biotechnology executive Thomas Mitchell has relocated to Australia to lead start-up BiomeBank, Australia’s first public stool bank and microbiome therapeutics company.

BiotechDispatch (11 February 2021): Telix Pharmaceuticals (ASX:TLX) has announced a research cooperation agreement with Heidelberg University Hospital in Germany (UKHD) to develop next-generation theranostic radiopharmaceuticals for urologic oncology.

BiotechDispatch (9 February 2021): BioCurate, an independently operated joint venture between the University of Melbourne and Monash University and with support of the Victorian state government, has announced the appointment of Dr Damien Bates as acting CEO.

BiotechDispatch (9 February 2021): Pharmaxis (ASX:PXS) has triggered a US$3 million milestone payment after exporting the first shipment of its locally developed and manufactured drug BRONCHITOL (mannitol) to the US.

BiotechDispatch (4 February 2021): Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has published positive data from a human clinical study examining the safety, tolerability and efficacy of its BTX 1801 antimicrobial product.

BiotechDispatch (4 February 2021): Melbourne-based Starpharma (ASX:SPL) says it is on target and ready to launch its 'Viraleze' nasal spray in the UK and other European countries in March.

BiotechDispatch (2 February 2021): The US government is investing in Australian digital diagnostics company Ellume with a $231.8 million agreement to accelerate domestic US production of its COVID-19 home tests.

BiotechDispatch (2 February 2021): Australian regenerative medicine company Orthocell (ASX:OCC) has announced the publication of a successful case study focused on the combination of its CelGro collagen medical device with autologous tenocyte implantation for the surgical repair of a large degenerate tear of the gluteal medius tendon.

BiotechDispatch (21 January 2021): Researchers at the QIMR Berghofer Medical Research Institute in Brisbane have launched a clinical trial of a new cellular immunotherapy treatment.

BiotechDispatch (14 January 2021): Noxopharm (ASX:NOX) has announced that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth and final dosage cohort.

BiotechDispatch (14 January 2021): Telix Pharmaceuticals (ASX:TLX) and partner ARTMS have announced they have successfully produced Telix's prostate cancer imaging product, TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11).

BiotechDispatch (12 January 2021):  Pharmaxis (ASX:PXS) has received a US$7 million milestone payment from its US licensee Chiesi following the recent FDA approval of BRONCHITOL (mannitol) for the treatment of cystic fibrosis.

BiotechDispatch (17 December 2020): The US FDA has granted emergency use authorisation to a new rapid at-home COVID-19 antigen test developed by Australian digital diagnostic company Ellume.

BiotechDispatch (17 December 2020): SUDA Pharmaceuticals (ASX:SUD), a company focussed on oromucosal drug delivery, has announced it has received "firm commitments" for a placement to raise over $2.7 million.

BiotechDispatch (15 December 2020):  Antisense Therapeutics (ASX:ANP) says it has received notification that the European Commission has designated ATL1102 as an orphan medicinal product for Duchenne muscular dystrophy.

BiotechDispatch (10 December 2020): The Queensland government has announced it will make a $50 million investment in Brisbane-based digital diagnostics company Ellume to support the ramping up of its production of diagnostic tests for common infectious diseases, including COVID-19.

BiotechDispatch (10 December 2020): Immunotherapy company Immutep (ASX:IMM) has announced what it describes as promising overall survival data from a breast cancer trial of its eftilagimod alpha and that its Chinese partner, EOC Pharma, will commence a new phase two clinical trial in up to 152 patients.

BiotechDispatch (8 December 2020): The TGA has granted Telix Pharmaceuticals' (ASX:TLX) prostate cancer imaging product TLX591-CDx priority review status.

BiotechDispatch (3 December 2020): Australian clinical-stage drug development company Noxopharm (ASX:NOX) has completed a $23 million share placement to professional, institutional, and sophisticated investors.

BiotechDispatch (1 December2020): Clinical-stage company Dimerix (ASX:DXB) has announced its lead candidate DMX-200 will enter a second clinical study in COVID-19 patients.

BiotechDispatch (1 December 2020): Australian biotechnology company Telix Pharmaceuticals (ASX:TLX) has announced it will acquire Swiss-German counterpart TheraPharm for its portfolio of potential diagnostics and treatments for haematological diseases like blood cancer.

BiotechDispatch (27 November 2020):  Telix Pharmaceuticals (ASX:TLX) has filed a new drug application with the US FDA for its radiopharmaceutical targeting ProstateSpecific Membrane Antigen for the imaging of prostate cancer using Positron Emission Tomography.

BiotechDispatch (26 November 2020):  Sydney scientists investigating telomeres and stem cells have reported what a leading Australian researcher calls “the most unexpected result of my career’’.

BiotechDispatch (24 November 2020): Monash University has a new project that aims to use a range of new technologies to help address one of the world's most serious health issues, antimicrobial resistance.

BiotechDispatch (24 November 2020): Adelaide’s Carina Biotech has announced an agreement to create CAR-T cells targeted at a cancer stem cell marker that is abundant in solid tumours.

BiotechDispatch (19 November 2020):  QBiotics Group, a life sciences company developing novel anti-cancer and wound healing therapies, has announced the US FDA's Center for Veterinary Medicine (CVM) has approved its STELFONTA.

BiotechDispatch (12 November 2020): Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it has successfully completed a Pre-Investigational New Drug meeting with the US FDA's Office of Infectious Diseases for its lead antimicrobial program, BTX 1801.

BiotechDispatch (12 November 2020): Antisense Therapeutics (ASX:ANP) says it has received notification that the European Medicines Agency Committee for Orphan Medicinal Products has adopted a positive opinion on its submission for Orphan Drug designation on ATL1102 for duchenne muscular dystrophy.

BiotechDispatch (10 November 2020): Noxopharm (ASX:NOX) has announced its investigative cancer therapy Veyonda will be trialed with Bristol-Myers Squibb's immunotherapy OPDIVO (nivolumab).

BiotechDispatch (5 November 2020): A new report from CSIRO has found that while Australian investment in science and technology for disease preparedness has driven a strong response to COVID-19, there are still barriers to the adoption of innovation.

BiotechDispatch (3 November 2020): Pharmaxis has become one of the small number of local life science companies to secure FDA approval of an Australian, developed, discovered and manufactured product.

BiotechDispatch (3 November 2020): Telix Pharmaceuticals (ASX:TLX) has entered a strategic commercial partnership with China Grand Pharmaceutical and Healthcare Holdings for its portfolio of Molecularly-Targeted Radiation products.

BiotechDispatch (3 November 2020):  Immutep (ASX:IMM) has announced a new licence and collaboration agreement with Laboratory Corporation of America Holdings that will support the development of immuno-oncology products or services.

BiotechDispatch (29 October 2020): Cancer Trials Australia says it has recently marked the recruitment of the 10,000th oncology patient to trials managed on behalf of their member network of hospitals.

BiotechDispatch (29 October 2020): AbbVie has signed a new memorandum of understanding with Australian university joint venture BioCurate that is designed to accelerate the development of new medicines.

BiotechDispatch (27 October 2020):  Immutep (ASX:IMM) has signed an agreement with the University Hospital Pilsen in the Czech Republic that will enable an investigator-initiated randomised phase two clinical trial of its lead product candidate eftilagimod alpha (efti) in hospitalised patients with COVID-19.

BiotechDispatch (27 October 2020): Dimerix (ASX:DXB) says it has navigated another important step in the development of its lead compound DMX-200 for the treatment of kidney disease.

BiotechDispatch (22 October 2020): Biosceptre has announced an agreement with The University of Sydney and Children’s Medical Research Institute to establish a new research program on CAR-T cell immunotherapy.

BiotechDispatch (22 October 2020): Microbio says it has developed a new type of COVID-19 test that has the potential to determine not only if someone has the virus but could also indicate whether they are infectious.

BiotechDispatch (22 October 2020): AnteoTech (ASX:ADO) says it has received the results of an independent validation study of its COVID-19 Antigen Rapid Test using stored patient swab samples.

BiotechDispatch (20 October 2020): Proteomics International Laboratories (ASX:PIQ) has announced it has signed a distribution licensing agreement for the immunoassay version of the PromarkerD predictive test for diabetic kidney disease.

BiotechDispatch (20 October 2020): Melbourne-based ASX-listed biotechnology company Amplia Therapeutics (ASX:ATX) will develop a potential new pancreatic cancer therapy discovered by scientists at the Cancer Therapeutics CRC.

BiotechDispatch (13 October 2020): Industry minister Karen Andrews has announced federal government backing for a Brisbane-based manufacturing facility that will produce products for clinical trials.

BiotechDispatch (13 October 2020): Australian medical technology company LBT Innovations (ASX:LBT) has announced the sale of an APAS Independence with MRSA analysis module to the Limbach Group based in Germany.

BiotechDispatch (13 October 2020):  Australian clinical-stage biopharmaceutical company Opthea (ASX:OPT) has launched its initial public offering of American Depositary Shares.

BiotechDispatch (8 October 2020): Brisbane-based rapid digital diagnostics company Ellume has announced it has been awarded US$30million from the US National Institutes of Health to support the accelerated clinical testing and manufacturing scale-up of the company’s COVID-19 antigen tests.

BiotechDispatch (6 October 2020): Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced the successful completion of the institutional component of its capital raise.

BiotechDispatch (1 October 2020): Investors have welcomed positive news for Australian company Antisense Therapeutics with the FDA moving its treatment for duchenne muscular dystrophy one step closer to possible approval.

BiotechDispatch (29 September 2020): A new company called Nirtek has been set up to commercialise technology developed by researchers at the Baker Institute to detect unstable coronary plaques.

BiotechDispatch (29 September 2020): Australian antibody development company Patrys (ASX:PAB) says it has completed initial production and characterisation of PAT-DX3, a full-sized, humanised antibody version of its dimerised antibody fragment PAT-DX1.

BiotechDispatch (24 September 2020): Telix Pharmaceuticals (ASX:TLX) has submitted a New Drug Application to the US FDA for its radiopharmaceutical targeting Prostate-Specific Membrane Antigen for the imaging of prostate cancer using Positron Emission Tomography.

BiotechDispatch (24 September 2020): Melbourne-based privately owned Australian biotechnology Technovalia has partnered with the Vax4COVID Alliance and BioNet to start a phase one trial of the COVIGEN COVID-19 gene-based vaccine.

BiotechDispatch (22 September 2020): A startup company developing treatments for inflammatory diseases based on a research partnership between The University of Queensland and Trinity College Dublin has been acquired in a landmark deal.

BiotechDispatch (22 September 2020): Kazia said the collaboration will investigate the use of its investigational new drug, paxalisib (formerly GDC-0084), in primary central nervous system lymphoma.

BiotechDispatch (17 September 2020): Regenerative medicine company Orthocell (ASX:OCC) has announced the publication of positive pre-clinical and clinical results for the use of its CelGro in enhancing repair of critical bone defects in the 'Tissue Engineering' Journal.

BiotechDispatch (17 September 2020): CSIRO says a new report has revealed the opportunities for industries to leverage science and technology and help restore economic growth and resilience.

BiotechDispatch (15 September 2020): Adelaide-based CAR-T biotherapeutics company Carina Biotech has announced a co-development agreement with immuno-oncology company Glytherix it says could result in a promising new therapy that is effective in killing a range of cancers.

BiotechDispatch (15 September 2020): Melbourne-based clinical-stage biopharmaceutical company Dimerix (ASX:DSB) has updated on clinical trials of its drug candidate DMX-200 for kidney diseases.

BiotechDispatch (15 September 2020): Starpharma (ASX:SPL) says laboratory testing of its antiviral SPL7013 against COVID-19 has confirmed it is more than 99.9 per cent effective against the virus.

BiotechDispatch (10 September 2020): Researchers at the Children’s Medical Research Institute have published a new paper they say will help improve strategies for treating serious genetic disorders of the liver.

BiotechDispatch (10 September 2020): Melbourne researchers developing a potential new treatment for ovarian cancer have attracted investment that will support its progression through early testing and into clinical trials.

BiotechDispatch (9 September 2020):  A Brisbane-based medical oncologist has been announced as the recipient of the Merck-AGITG Clinical Research Fellowship in gastro-intestinal Cancer for 2021-22.

BiotechDispatch (3 September 2020): Australian digital diagnostics firm Ellume has extended its strategic partnership with global life sciences and diagnostics company Qiagen.

BiotechDispatch (3 September 2020): genomiQa has announced a new Brisbane-based validation study of its CapeDX whole-genome analysis platform in a partnership with Icon Group.

BiotechDispatch (3 September 2020): Health minister Greg Hunt has announced funding for a range of research projects aimed at developing treatments, diagnostics and a vaccine for COVID-19.

BiotechDispatch (1 September 2020): Australian biopharmaceutical contract development and manufacturing company Luina Bio has announced plans to expand its capacity to meet demand in the microbiome and recombinant biopharma markets.

BiotechDispatch (1 September 2020): Immutep (ASX:IMM) has announced it and research partner Monash University have received a grant under the ARC‘s Linkage Project scheme to support their research collaboration into LAG-3 for a further three years.

BiotechDispatch (27 August 2020): Australian vaccine development company BioDiem has announced the product launch of Changchun BCHT Biotechnology’s LAIV vaccine in China.

BiotechDispatch (27 August 2020): Prescient Therapeutics (ASX:PTX) has announced that it has received commitments to raise over $7 million before costs by way of a share placement to professional and sophisticated investors.

BiotechDispatch (25 August 2020): The University of Queensland says researchers have developed an innovative technique to improve cancer treatments using tumour biopsies less than 30 minutes after they are taken.

BiotechDispatch (25 August 2020): Australian company Cynata Therapeutics (ASX:CYP) says it has begun patient enrolment in its MEND (MEseNchymal coviD-19) trial.

BiotechDispatch (20 August 2020): Sydney-based Pharmaxis (ASX:PXS) says the US FDA has completed a safety review of the company’s Investigational New Drug application for its pan-LOX inhibitor PXS-5505 and given it permission to proceed with a new clinical trial.

BiotechDispatch (20 August 2020): Kazia Therapeutics (ASX:KZA), an Australian oncology-focused biotechnology company, has announced that the US FDA has granted Fast Track Designation (FTD) to its paxalisib (formerly GDC-0084) for the treatment of glioblastoma.

BiotechDispatch (18 August 2020): Australian company Hydrix (ASX:HYD) has announced the first supply and implant of its AngelMed Guardian device.

BiotechDispatch (18 August 2020):  Australian company Starpharma (ASX:SPL) has signed a new research partnership with Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical to develop several DEP nanoparticle formulations for an anti-infective drug

BiotechDispatch (13 August 2020): Australian company QBiotics (QGL) has announced a new agreement with US global biopharmaceutical company MSD.

BiotechDispatch (13 August 2020): CSIRO has announced it will work with the government, universities, industry and the wider community, on a new missions program to bolster Australia’s COVID-19 recovery.

BiotechDispatch (11 August 2020): Australian regenerative medicine company, Regeneus (ASX: RGS), has announced that Kyocera has signed a licence agreement to develop and commercialise Progenza for knee osteoarthritis in Japan.

BiotechDispatch (6 August 2020):Janssen has teamed up with Monash University for a research and development program to advance the development of inhaled oxytocin for the prevention of postpartum hemorrhage in developing countries.

BiotechDispatch (4 August 2020): Australian company Medlab Clinical (ASX.MDC) has reported positive data from the ongoing observational study of NanaBis that is in development as a non-opioid alternative for the treatment of cancer-induced bone pain.

BiotechDispatch (11 August 2020): CEO Dr Leearne Hinch said, “This core patent family provides intellectual property protection in the US and Europe for our BARD1-Ovarian and BARD1-Breast cancer tests in development for early detection of ovarian and breast cancers.”

BiotechDispatch (30 July 2020): Melbourne-based biopharmaceutical company Dimerix (ASX:DXB) has reported positive results from the clinical trial of its drug candidate DMX-200.

BiotechDispatch (30 July 2020): Perth-based SUDA Pharmaceuticals (ASX:SUD) has announced the TGA has approved its lead product ZolpiMist (zolpidem tartrate) for the treatment of short-term insomnia in adults.

BiotechDispatch (28 July 2020): Starpharma (ASX:SPL) has announced the opening of the MD Anderson Cancer Center as another site for the phase one trial of AZD0466 - AstraZeneca’s first DEP product.

BiotechDispatch (28 July 2020): Australian company Proteomics International (ASX:PIQ) says it has secured patents for PromarkerD, a low cost, high throughput predictive test for diabetic kidney disease, in Brazil and Canada.

BiotechDispatch (23 July 2020): German-based Merck has entered a new licensing agreement with the QIMR Berghofer Medical Research Institute covering novel cancer immunotherapies.

BiotechDispatch (16 July 2020): Australian company Biointelect is playing a leading role in the development of anti-malarial KODATEF (tafenoquine) for the treatment of COVID-19 injection.

BiotechDispatch (16 July 2020):  Australian company Nyrada (ASX:NYR) has reported results from a preclinical pharmacokinetic study of its two lead brain injury drug candidates.

BiotechDispatch (14 July 2020): Merck has extended an existing agreement with Australian biopharmaceutical formulation company Sypharma to support the manufacture of Vaxine's investigative vaccine against COVID-19.

BiotechDispatch (9 July 2020): Sydney-based anti-infective company Recce Pharmaceuticals (ASX:RCE) has announced an Antiviral SARS-CoV-2 Screening Program Agreement with CSIRO and the University of Melbourne's Doherty Institute.

BiotechDispatch (9 July 2020):  Telix Pharmaceuticals (ASX:TLX) says it has entered into a strategic collaboration agreement with US-based RefleXion Medical.

BiotechDispatch (7 July 2020): Cochlear (ASX:COH) has announced US FDA approval for four new products the company said will now be commercialised released over the next few months.

BiotechDispatch (7 July 2020): Brisbane-based Zucero Therapeutics has announced what it describes as 'promising' laboratory-based findings for its lead clinical candidate pixatimod and COVID-19

BiotechDispatch (2 July 2020): Australian regenerative medicine company Orthocell (ASX:OCC) has announced the completion of recruitment in the Ortho-ATI shoulder tendon study it is conducting in collaboration with DePuy Synthes Products, part of the Johnson & Johnson Medical.

BiotechDispatch (9 July 2020): Australian company Cellmid (ASX:CDY) has signed an exclusive distribution agreement with Hong Kong-based company Immunodiagnostics for laboratory-based, quantitative Enzyme-Linked Immunosorbent Assays (ELISA’s) and a point of care serology test for SARS-CoV-2 for Australia and New Zealand.

BiotechDispatch (30 June 2020): Australian immunotherapy company Immutep (ASX:IMM) has announced it has enrolled and safely dosed the last patient for stage two of Part A of its TACTI-002 Phase 2 trial.

BiotechDispatch (25 June 2020): CSL Behring has acquired global rights to an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of haemophilia B from uniQure.

BiotechDispatch (25 June 2020): Melbourne-based Planet Innovation, a health innovation and commercialisation company, has announced a partnership with US company Truvian to design and manufacture a new point-of-care blood testing device.

BiotechDispatch (18 June 2020): Noxopharm (ASX:NOX) has announced the commencement of its NOXCOVID clinical program with a planned phase one trial in Europe.

BiotechDispatch (23 June 2020): Biotron (ASX:BIT) has announced it will present the latest data on BIT225 HIV-1 at the 23rd International AIDS Conference (AIDS 2020: Virtual) in July.

BiotechDispatch (23 June 2020):Clinical-stage biopharmaceutical company Dimerix (ASX:DXB) has announced the placement of 16,222,580 fully paid ordinary shares to institutional and sophisticated investors at a price of $0.36 per share to raise $5.8 million before costs.

BiotechDispatch (18 June 2020): Australian-based molecular diagnostic company SpeeDx has signed a new agreement with Roche that will expand global access to its infectious disease and antibiotic resistance tests and technology.

BiotechDispatch (18 June 2020): BioCurate has announced a new agreement with leading Australian commercialisation fund Uniseed to collaborate on projects of specific interest and facilitate commercialisation of intellectual property at the University of Melbourne.

BiotechDispatch (16 June 2020): An orally administered treatment for type 2 diabetes, which is designed to mirror the effect of gastric bypass surgery in improving sugar control in diabetes patients, has received a Series A investment of $29 million.

BiotechDispatch (11 June 2020): Australian biotechnology company AdAlta (ASX:1AD) says it has received Human Research Ethics Committee (HREC) approval to commence a phase one clinical trial of its lead product candidate, AD-214.

BiotechDispatch (11 June 2020): Australian company Opthea (ASX:OPT) has announced topline results from a trial evaluating its biologic OPT-302 in combination with Bayer's PBS-listed EYLEA (aflibercept).

BiotechDispatch (9 June 2020): According to Dr Anand Gautam, executive director and emerging science lead at Pfizer Worldwide R&D, “Australia and the region remain a key geography for Pfizer’s R&D partnerships due to the very high quality of scientific discoveries here in areas such as biochemistry and immunology."

BiotechDispatch (9 June 2020): CSL has announced it will partner with the Coalition for Epidemic Preparedness Innovations to accelerate the development and manufacture of the COVID-19 vaccine under development at The University of Queensland.

BiotechDispatch (4 June 2020): Dimerix (ASX:DXB) has announced that its DMX-200 has been selected for inclusion in the protocol as a new treatment arm in a clinical trial for Acute Respiratory Distress Syndrome as a result of COVID-19.

BiotechDispatch (4 June 2020): A COVID-19 response package to support the life science sector, which is valued at over $170 billion, is urgently needed says Dr Chris Nave, CEO of Australia’s largest life science investment fund.

BiotechDispatch (2 June 2020): Noxopharm (ASX: NOX) has updated on its presentation of two sets of clinical trial data relating to the development of NOX66 (Veyonda) as a treatment of end-stage cancer.

BiotechDispatch (2 June 2020): Investors have welcomed new data from Australian biopharmaceutical company Immutep from a trial involving its eftilagimod alpha in combination with MSD's PBS-listed immunotherapy KEYTRUDA (pembrolizumab).

BiotechDispatch (2 June 2020): CSL has opened applications for its Centenary Fellowships that are offered to mid-career scientists wanting to undertake medical research at an Australian academic institute.

BiotechDispatch (28 May 2020): US-based biotechnology company Novavax initiated patients in an Australian-based phase one trial of its investigational COVID-19 vaccine this week with the support of clinical research organisation, Nucleus Network.

BiotechDispatch (28 May 2020): Australian medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has announced a commercial supply agreement with Tasmanian Alkaloids (TasAlk) to manufacture the Insomnia and HOPE medicinal cannabis formulations.

BiotechDispatch (26 May 2020): Antisense Therapeutics (ASX:ANP) has announced the phase 2 trial of its immunomodulatory therapy (ATL1102) for Duchenne Muscular Dystrophy has met its primary endpoint and will now advance to a phase 2b study.

BiotechDispatch (26 May 2020): Australian company Nyrada (ASX:NYR) has announced a preclinical pharmacokinetic study of its lead candidate compounds has found they can cross the blood-brain-barrier (BBB) in the intact uninjured animal brain.

BiotechDispatch (21 May 2020): Australian venture capital firm OneVentures has announced the appointment of John Westwater and Kelly Constable to its healthcare team.

BiotechDispatch (19 May 2020): Melbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the inventor of the Deoxymab technology platform, Dr James Hansen of the Yale School of Medicine, has been awarded a research grant from the US National Institutes of Health.

BiotechDispatch (19 May 2020):  ResApp Health (ASX:RAP) says its ResAppDx-EU smartphone-based acute respiratory diagnostic test has been under evaluation at a federal government-funded COVID-19 respiratory clinic in Brisbane for the past month.

BiotechDispatch (14 May 2020): Australian cell-therapy company Mesoblast (ASX:MSB) says it has successfully completed a $138 million capital raise via a placement of 43 million shares to existing and new institutional investors at a price of $3.20 per share. 

BiotechDispatch (14 May 2020): Noxopharm (ASX:NOX) has announced a $7.9 million capital raise its says will go towards progressing its oncology programs as well as its recent move into infection.

BiotechDispatch (7 May 2020):  Melbourne-based biotechnology company Tessara Therapeutics has raised $2.7 million through what it described as a significantly over-subscribed round one capital raise.

BiotechDispatch (7 May 2020): Mesoblast (ASX:MSB) says the first patients have been dosed in its 300-patient randomised placebo-controlled Phase 2/3 trial in the US of its allogeneic cellular medicine remestemcel-L in COVID-19 infected patients with moderate to severe acute respiratory distress syndrome on ventilator support.

BiotechDispatch (5 May 2020): US-based clinical-stage biotechnology company Novavax has selected Australian speciality laboratory 360biolabs to conduct sample analysis for the clinical trial of its COVID-19 recombinant spike protein nanoparticle vaccine (NVX-CoV2373).

BiotechDispatch (30 April 2020): Noxopharm (ASX:NOX) has released details of the radiographic review of its DARRT-1 clinical study and says it shows a major benefit from a combination of Veyonda and low-dose radiotherapy.

BiotechDispatch (28 April 2020): Australian company Pharmaxis (ASX:PXS) says positive results from phase 1b and long-term toxicity studies of its oral anti‐fibrotic LOX inhibitor PXS‐5505 mean it is now progressing to a phase 2 study for the treatment of the rare bone cancer, myelofibrosis. 

BiotechDispatch (23 April 2020): Novartis says it has reached an agreement with the US FDA to proceed with a phase 3 clinical trial of hydroxychloroquine in patients hospitalised with COVID-19 disease.

BiotechDispatch (23 April 2020): Prescient Therapeutics (ASX:PTX) says the Phase 1b study of PTX-100 will proceed to the next dose level following successful completion of the first cohort of patients and demonstrating acceptable safety.

BiotechDispatch (16 April 2020): According to the company, SPL7013 inhibited the infection of cells with the SARS-CoV-2 virus and the finding was validated by replicate testing against a positive control compound, remdesivir (Gilead), which is considered a leading candidate for the treatment of COVID-19.

BiotechDispatch (14 April 2020): Australian company Radium Capital says it has seen a 161 per cent jump in the number of health and social care companies applying for advances over the past 12 months, with new inquiries from the sector accelerating in the wake of the COVID-19 pandemic.

BiotechDispatch (14 April 2020): Grey Innovation has announced it is leading a Victorian industry consortium that has secured a $31.3 million contract with the federal government to build 2,000 ventilators as part of Australia’s response to the COVID-19 pandemic.

BiotechDispatch (9 April 2020):  Perth-based medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has announced it has demonstrated its formulation ZLT-101 works for people suffering insomnia. 

BiotechDispatch (9 April 2020):  Australian company Immutep (ASX:IMM) has announced it has worked with its partner EOC Pharma to review study results and they have confirmed plans to continue advancing Efti in metastatic breast cancer.

BiotechDispatch (9 April 2020): Cochlear (ASX:COH) says it has obtained US FDA approval for its Remote Check solution, the first telehealth patient assessment tool for cochlear implant recipients.

BiotechDispatch (7 April 2020):Australian cell therapy company Mesoblast (ASX:MSB) has announced the US FDA has cleared one of its investigational therapies for trials in acute respiratory distress syndrome caused by COVID-19. 

BiotechDispatch (7 April 2020):  “We are excited to be able to contribute to Australia’s comprehensive effort to manage this pandemic,” said Cellmid CEO Maria Halasz.

BiotechDispatch (2 April 2020): CSIRO says it has commenced the first stage of testing potential vaccines against COVID-19. It said the testing, expected to take three months, is underway at its high-containment biosecurity facility in Geelong. 

BiotechDispatch (2 April 2020): Dr Jonathan Anderson, Seqirus' Asia Pacific Head of Medical Affairs, told BiotechDispatch the company has seen "strong early demand" for flu vaccines.

BiotechDispatch (2 April 2020):  The company described this first approval as a major milestone that allows for the OncoSil device to be marketed and sold within the European Union and the UK.

BiotechDispatch (31 March 2020): Clinical stage biopharmaceutical company Opthea (ASX:OPT) says it has completed patient dosing and all follow-up week 12 patient visits in the Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with Bayer's EYLEA (aflibercept) for the treatment of diabetic macular edema.

BiotechDispatch (31 March 2020): A South Australian packaging manufacturer has reached agreement with the federal and state governments to produce 145 million masks – 100 million for the National Medical Stockpile and 45 million for South Australia.

BiotechDispatch (26 March 2020): Cochlear (ASX:COH) has completed an $880 million placement saying demand was high to the point it was fully allocated to existing institutional shareholders.

BiotechDispatch (26 March 2020): Novartis says updated data has confirmed the significant clinical benefit of its gene therapy ZOLGENSMA (onasemnogene abeparvovec) for patients with spinal muscular atrophy.

BiotechDispatch (26 March 2020): Bill Ferris AC, a pioneer of the Australian venture capital sector and an architect of the federal government’s $500 million Biomedical Translation Fund, has been appointed Chair of the Medical Research Commercialisation Fund.

BiotechDispatch (24 March 2020): New data has been published indicating the potential of a new vaccine technology being developed by Australian biotechnology company Vaxxas.

BiotechDispatch (24 March 2020): Sydney-based clinical-stage regenerative medicine company Regeneus (ASX:RGS) has received a non-refundable milestone payment of approximately $1.6 million (100 million Japanese Yen) from Kyocera Corporation.

BiotechDispatch (20 March 2020):  Queensland-based Luina Bio has announced they have entered into a Memorandum of Understanding with Griffith University targeting the development of a vaccine against COVID-19.

BiotechDispatch (20 March 2020): This new collaboration comes just days after Moderna Therapeutics' confirmed it had begun the first human trial of an investigational vaccine against COVID-19. Other companies, including Sanofi, Gilead and AbbVie, are testing existing medicines as potential treatments for COVID-19.

BiotechDispatch (5 March 2020): The federal and Victorian governments are combining to establish a new National Drug Discovery Centre (NDDC) at the Walter and Eliza Hall Institute of Medical Research.

BiotechDispatch (5 March 2020): Noxopharm (ASX:NOX) has announced that the last patient has been enrolled and safely dosed in the ongoing LuPIN Phase 1/2 clinical trial being conducted by St Vincent’s Hospital Sydney.

BiotechDispatch (4 March 2020): Australian vaccine development company BioDiem (ASX:BDM) has announced the approval of Changchun BCHT Biotechnology Co’s LAIV vaccine in China by the Chinese National Medical Products Administration, formerly known as the Chinese FDA.

BiotechDispatch (3 March 2020): According to CEO and managing director Dr James Campbell, “Following ongoing discussions at several partnering events, Patrys has expanded efforts to leverage the platform technology applications of the Deoxymab technology."

BiotechDispatch (27 February 2020): CEO Graham Kelly PhD said, “Bringing Veyonda to market for late-stage prostate cancer remains our commercial imperative. This IND grant for a less common cancer type contributes to that overall commercial objective in several ways."

BiotechDispatch (20 February 2020): The Sydney-based biotechnology Immutep (ASX:IMM) company has released new positive data from a trial involving its immunotherapy in combination with MSD's KEYTRUDA (pembrolizumab).

BiotechDispatch (18 February 2020): Researchers say they have developed a blood test that measures the body’s own immune response to improve the diagnosis of ovarian cancer.

BiotechDispatch (18 February 2020): Cochlear (ASX:COH) has reported a 9 per cent increase in sales revenue for the six months to the end of December 2019 driven by a 14 per cent rise in implant revenue.

BiotechDispatch (13 February 2020): A significant jump in net profit after tax for CSL in the six months to 31 December 2019 with strong growth in sales of immunoglobulin and flu vaccine.

BiotechDispatch (13 February 2020): SpeeDx, the developer of clinical diagnostics to support patient outcomes, has raised $15 million in additional series B equity investment from US-based Northpond Ventures. 

BiotechDispatch (6 February 2020):  Regenerative medicine company Orthocell (ASX:OCC) has announced it has been granted Canadian and Japan divisional patents for CelGro.

BiotechDispatch (6 February 2020): GE Healthcare Life Sciences and the Sydney-based Children’s Medical Research Institute have announced a collaboration to drive the development of new affinity ligands for the purification of adeno-associated viral vectors used in gene therapies.

BiotechDispatch (4 February 2020): Mesoblast (ASX:MSB) has submitted its completed Biologics License Application (BLA) to the US Food and Drug Administration for RYONCIL (remestemcel-L).

BiotechDispatch (30 January 2020): Cell Therapies, a leader in the development, manufacturing and distribution of cell-based therapies, has welcomed an agreement with Novartis to produce their CAR-T cell therapy product KYMRIAH (tisagenlecleucel) in Melbourne.

BiotechDispatch (30 January 2020): Didier Dargent, who previously led the Novartis Oncology business in China, contrasted the "disruptive" nature of cell therapies with traditional pharmaceuticals.

BiotechDispatch (28 January 2020): Research Australia has used its 2020-21 Budget submission to call on the federal government to scrap its proposed cuts to the R&D Tax Incentive and instead focus on enhancing compliance with the program.

BiotechDispatch (28 January 2020): Zelira Therapeutics (ASX:ZLD) has announced a collaboration with the US-based Parkinson’s Foundation to gather insights from people with PD about their understanding of and use of medical cannabis and hemp-derived therapies.

BiotechDispatch (21 January 2020 ): Patrys (ASX:PAB), an Australian therapeutic antibody development company, has announced the upcoming presentation of scientific data regarding its lead candidate, PAT-DX1. 

BiotechDispatch (17 December 2019): The Children’s Medical Research Institute has welcomed a $25 million commitment by the NSW Government for a new advanced viral vector manufacturing facility at Westmead.

BiotechDispatch (17 December 2019): PolyNovo (ASX:PNV) has announced that NovoSorb BTM has been granted a certificate of conformance (CE Mark) approval for sale throughout UK/Ireland and the European Union.

BiotechDispatch (10 December 2019): Epichem has been recognised at the 31st Western Australian Industry and Export Awards, receiving the WA Export Award for International Health.

BiotechDispatch (3 December 2019): Australian company Noxopharm (ASX:NOX) has reported positive end-of-study data from its DARRT-1 Phase 1b trial of Veyonda.

BiotechDispatch (3 December 2019): Zelira Therapeutics, formerly known as Zelda Therapeutics (ASX:ZLD), has announced the completion of the 100 per cent acquisition of Ilera Therapeutics.

BiotechDispatch (3 December 2019): Australian biotechnology company Opthea (ASX:OPT) has announced it has received commitments from sophisticated and institutional investors to raise $50 million via a private placement.

BiotechDispatch (28 November 2019): SUDA Pharmaceuticals (ASX:SUD), a company focused on oro-mucosal drug delivery, has announced the appointment of Dr Michael Baker as its CEO, commencing 2 January 2020.

BiotechDispatch (28 November 2019): The Peter MacCallum Cancer Centre says a new study has demonstrated the potential for artificial intelligence to help reduce the time for clinicians to match lung cancer patients to relevant clinical trials.

BiotechDispatch (26 November 2019):  Australian oncology company Kazia Therapeutics (ASX:KZA) has released interim data from its ongoing phase 2 study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer.

BiotechDispatch (21 November 2019): Starpharma (ASX:SPL) has announced it has been granted marketing approval for its VivaGel condom in Europe. 

BiotechDispatch (21 November 2019): Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Professor Prasad S. Adusumilli, MD FACS FCCP, to its newly formed oncolytic virotherapy Scientific Advisory Board.

BiotechDispatch (19 November 2019): Cochlear said it will commence the commercial rollout of the system in the US during the second half of FY20, with availability in other countries subject to regulatory approvals.

BiotechDispatch (19 November 2019): The release of research conducted over six years has found no link between cholesterol-lowering statins and memory loss.

BiotechDispatch (7 November 2019): Planet Innovation has announced it is partnering with Melbourne-based start-up Scinogy to manufacture a new cell processing system that is being commercialised global biotechnology company Thermo Fisher Scientific.

BiotechDispatch (7 November 2019):  Medicinal cannabis company Zelda Therapeutics (ASX:ZLD) has announced that its clinical trial for insomnia is now fully enrolled. 

BiotechDispatch (5 November 2019): Australia-based Agilex Biolabs, widely recognised as the Asia-Pacific region’s leading bioanalytical laboratory for clients conducting preclinical and clinical trials, announced at AusBiotech 2019 last week that it has been selected as a Top 10 Bioanalytical Services Provider by PharmaTech Magazine.

BiotechDispatch (5 November 2019): The FDA has granted fast-track designation to Bionomics' (ASX:BNO) BNC210 development program for the treatment of Post-Traumatic Stress Disorder (PTSD) and other trauma-related and stressor-related disorders. 

BiotechDispatch (24 October 2019): Cochlear chair Rick Holliday-Smith said the past financial year saw the company focus on building awareness and market access to cochlear implants, expanding its marketing activities and customer servicing capability while maintaining a commitment to product innovation.

BiotechDispatch (22 October 2019): Sydney-based Noxopharm (ASX:NOX) has updated on interim data from the DARRT-1 study where Veyonda is being tested in patients with prostate cancer which is late-stage, progressive and metastatic.

BiotechDispatch (17 October 2019): Immutep (ASX:IMM) has announced "mature positive efficacy" data from its TACTI-mel Phase 1 clinical study combining its lead product candidate, eftilagimod alpha, with MSD's KEYTRUDA (pembrolizumab) in metastatic melanoma.

BiotechDispatch (15 October 2019): Opthea (ASX:OPT) has announced the presentation of additional data from the recently completed 366 patient Phase 2b randomised controlled wet AMD study of OPT-302.

BiotechDispatch (15 October 2019):  Two Australian scientists have each been awarded five year $1.25 million CSL Centenary Fellowships for research looking at ways to improve treatments for two of the world’s biggest health challenges - malaria and cancer.

BiotechDispatch (15 October 2019): CSL has celebrated the 25th anniversary of listing on the Australian Stock Exchange (ASX) with a ceremonial bell ring at market open.

BiotechDispatch (10 October 2019): Australian regenerative medicine company Orthocell (ASX:OCC) has announced positive interim clinical results for the use of its CelGro for enhancing repair of peripheral nerves.

BiotechDispatch (10 October 2019): Mark Glover, Australia and New Zealand country manager of health technology company Medidata, says enhancing the design and conduct of clinical trials means putting patients at the centre of decision-making.

BiotechDispatch (10 October 2019): Medicinal cannabis company Zelda Therapeutics has announced a "merger of equals" with privately-held US-based counterpart Ilera Therapeutics.

BiotechDispatch (8 October 2019): BARD1 Life Sciences (ASX:BD1), a medical technology company developing non-invasive cancer diagnostics, announced it has reached the phase three milestone of its contracted assay development program to transfer its BARD1 assay to the Luminex platform.

BiotechDispatch (3 October 2019): Noxopharm (ASX:NOX) has provided further information on the upcoming release of clinical data concerning its lead drug candidate, Veyonda, saying it "now sees an important and exciting story emerging".

BiotechDispatch (3 October 2019): According to Opthea CEO and managing director, Dr Megan Baldwin, “This R&D tax incentive credit of A$14.6 million increases the company’s cash balances to over A$30 million and will contribute to the execution and delivery of outcomes from our clinical trials of OPT-302 in both wet AMD and DME”.

BiotechDispatch (1 October 2019): Radiopharmaceutical company Cyclopharm (ASX: CYC) has announced four management appointments.

BiotechDispatch (24 September 2019): GSK has paid Australian immunotherapy company Immutep (ASX:IMM) a $7.4 million milestone payment after the first patient was dosed in the phase 2 study of GSK2831781 in ulcerative colitis.

BiotechDispatch (24 September 2019): A new local agreement for Pfizer with the company sponsoring research at the University of Melbourne to identify and validate new targets for cancer therapy.

BiotechDispatch (19 September 2019): Australian regenerative medicine company Cynata Therapeutics (ASX:CYP) has announced Fujifilm has exercised its license option in graft-versus-host disease.

BiotechDispatch (19 September 2019): Melbourne-based company AdAlta (ASX:1AD) has signed a commercial agreement for its i-body platform with global medical technology firm, GE Healthcare. 

BiotechDispatch (17 September 2019): Sydney-based oncology biotechnology company Kazia Therapeutics, formerly known as Novogen, has been recognised at the 2019 ANZLF Trans-Tasman Innovation and Growth Awards.

BiotechDispatch (17 September 2019): Noxopharm (ASX:NOX) has announced that scientific abstracts on interim data relating to its DARRT-1 prostate cancer treatment study have been accepted for inclusion in two major oncology conferences.

BiotechDispatch (12 September 2019): CSL made the region's top ten while 14 small to medium-sized Australian companies made the top 100, according to a new report on biopharmaceutical innovation in Asia-Pacific

BiotechDispatch (12 September 2019): Australian company Mesoblast has entered a new partnership with German company Grünenthal for the further development and commercialisation of a cell therapy for chronic low back pain.

BiotechDispatch (10 September 2019): The share price of the Australian company developing a new eye therapy has quadrupled in recent weeks with its market capitalisation topping $900 million.

BiotechDispatch (5 September 2019):  Medical device company Cook Medical is celebrating 40 years of manufacturing in Australia - its team has grown from a dozen people to more than 600.

BiotechDispatch (5 September 2019): Cell Therapies (CTPL), a manufacturer and distributor of cell-based therapies, has been granted a product class (T-cells) GMP manufacturing licence by the TGA for commercial supply of these cells.

BiotechDispatch (5 September 2019): Novartis' Ronenn Roubenoff says the transformational impact of technologies like cell and gene therapy means companies are facing a "go big or go home" challenge.

BiotechDispatch (3 September 2019): German biopharmaceutical company Grünenthal has entered a new collaboration with UniQuest, The University of Queensland’s commercialisation company, to develop novel, non-opioid drug therapies derived from the group of alpha-conotoxins as analgesic and disease-modifying treatments of chronic neuropathic pain.

BiotechDispatch (29 August 2019): Starpharma (ASXSPL) has announced what it describes as promising efficacy signals in its ongoing clinical trials for both DEP cabazitaxel and DEP docetaxel. 

BiotechDispatch (27 August 2019): Regenerative medicine company Orthocell (ASX:OCC) has announced a Japanese patent for CelGro collagen rope.

BiotechDispatch (22 August 2019): Noxopharm (ASX:NOX) has provided an update on results from a series of proof-of-principle experiments in mice that are exploring the interaction between Veyonda and radiotherapy in a novel treatment regimen known as DARRT.

BiotechDispatch (20 August 2019): Cochlear (ASX:COH) has announced its full-year 2019 result with sales revenue up 7 per cent to $1.446 billion and net profit up 13 per cent to $276.7 million.

BiotechDispatch (20 August 2019): According to Starpharma CEO, Dr Jackie Fairley, “We are very pleased to receive our first regulatory approvals of VivaGel BV in Asia."

BiotechDispatch (15 August 2019): CSL has announced a strong full-year result with net profit after tax up 17 per cent to US$1.919 billion on the back of an 11 per cent jump in revenue.

BiotechDispatch (15 August 2019): Sydney-based company Noxopharm is developing a new approach to cancer treatment that is designed to convert 'cold' tumours to 'hot' so they can be recognised by the immune system.

BiotechDispatch (13 August 2019): Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) says it has completed recruitment of patients into Part B of its phase 1 clinical study of Cantrixil in ovarian cancer.

BiotechDispatch (8 August 2019): Opthea (ASX:OPT), an Australian clinical-stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has reported positive results from its Phase 2b trial of OPT-302 for wet age-related macular degeneration.

BiotechDispatch (8 August 2019): CSL has announced plans to relocate its global corporate headquarters and laboratories to the heart of Melbourne's Parkville biomedical precinct.

BiotechDispatch (6 August 2019): Imagion Biosystems (ASX:IBX) says it has filed pre-submission with the US Food and Drug Administration (FDA), the first step in gaining approval to commence its first-in-human study.

BiotechDispatch (1 August 2019): AdAlta (ASX: 1AD), an Australian biotechnology company on its lead i-body therapeutic AD-214 for human clinical trials for Idiopathic Pulmonary Fibrosis, has appointed Dr Rosalind Wilson to the role of non-executive director.

BiotechDispatch (1 August 2019): In a statement, Telix said under the terms of the agreement it will collaborate with Merck to conduct combination studies with several of the German company's molecules in combination with two of its MTR therapeutic programs.

BiotechDispatch (30 July 2019): Australian company Alterity Therapeutics (ASX:ATH), formerly known as Prana Biotechnology, says it has successfully completed its phase 1 study of neuroscience candidate PBT434

BiotechDispatch (30 July 2019): A 3D printer that can print replicas of different types of cancers and surrounding cells has won one of Australia's major design awards.

BiotechDispatch (25 July 2019): Regenerative medicine company Orthocell (ASX:OCC) has announced positive pre-clinical results for the use of CelGro in enhancing repair of severed peripheral nerves.

BiotechDispatch (25 July 2019): Antisense Therapeutics (ASX:ANP) has announced that five patients have completed their 24 weeks of dosing in the phase 2 clinical trial of the company's immunomodulatory therapy, ATL1102, for Duchenne Muscular Dystrophy.

BiotechDispatch (23 July 2019):  Japanese company Sumitomo Dainippon Pharma has moved to acquire Australian cell therapy company Cynata Therapeutics (ASX:CYP).

BiotechDispatch (23 July 2019): Opthea (ASX:OPT) has announced that the timing of the primary analysis from its ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) will be brought forward by one quarter.

BiotechDispatch (23 July 2019): Zelda Therapeutics (ASX:ZLD) has entered a strategic collaboration with Australian-based Emerald Clinics to access clinical data from patients treated with medicinal cannabis for pain and insomnia.

BiotechDispatch (18 July 2019): Johnson & Johnson Innovation has recognised six female undergraduate Griffith University students with awards aimed at supporting their education in science, technology, engineering, mathematics, manufacturing and design.

BiotechDispatch (18 July 2019): Melbourne-based Telix Pharmaceuticals (ASX:TLX) has announced the successful completion of an oversubscribed private placement to professional and sophisticated investors.

BiotechDispatch (18 July 2019): The Australian subsidiary of Servier has partnered with Melbourne-based BioCurate to share commercial and scientific expertise with the aim of accelerating the discovery of new therapeutics and drugs.

BiotechDispatch (18 July 2019): The Australian subsidiary of Servier has partnered with Melbourne-based BioCurate to share commercial and scientific expertise with the aim of accelerating the discovery of new therapeutics and drugs.

BiotechDispatch (16 July 2019): Australian immuno-oncology company Imugene (ASX:IMU) has boosted its investigational portfolio through the acquisition of local counterpart Vaxinia with global rights to a new oncolytic virus technology.

BiotechDispatch (16 July 2019): Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced new data from studies recently conducted involving its cannabidiol antimicrobial platform and a new development program ‘AB 2367’.

BiotechDispatch (18 June 2019): A new report has found that emerging companies, most with no presence in Australia, are responsible for over 90 per cent of gene, cell and nucleotide therapies currently in late-stage pipelines.

BiotechDispatch (18 June 2019): Monash Health has become the second hospital to join the Rhythm Biosciences (ASX:RHY) prospective clinical trial of ColoSTAT - its blood test for the early detection of colorectal cancer.

BiotechDispatch (18 June 2019): Anteo Diagnostics (ASX:ADO) has signed a collaboration agreement with California based Point-of-Care (POC) company Lumos Diagnostics.

BiotechDispatch (13 June 2019): Melbourne-based Telix Pharmaceuticals (ASX:TLX) has announced the extension of its research collaboration with the Institute for Radiation Sciences (IRS), Osaka University and the Department of Nuclear Medicine and Tracer Kinetics at Osaka University Graduate School of Medicine.

BiotechDispatch (13 June 2019): Digital health company ResApp Health (ASX:RAP) has announced it has received $1.785 million from its R&D tax incentive claim for the financial year ending 30 June 2018.

BiotechDispatch (11 June 2019): Perth-based Proteomics International Laboratories (ASX:PIQ) says it has been invited to feature on the American Diabetes Association TV News Network during the ADA 79th Scientific Sessions conference in San Francisco.

BiotechDispatch (6 June 2019): Australian company Microba has launched an R&D program at BIO in Philadelphia focused on the prevalent and incurable Inflammatory Bowel Disease.

BiotechDispatch (6 June 2019): Sydney-based Immutep (ASX:IMM) has announced that the first patient in the INSIGHT-004 phase 1 clinical trial has been enrolled in Germany and has received the first dose of treatment.

BiotechDispatch (4 June 2019): UniQuest, The University of Queensland’s commercialisation company, has announced it will partner with Pfizer’s Centers for Therapeutic Innovation on the creation and development of a drug candidate for the treatment of cancer.

BiotechDispatch (4 June 2019): The fellowships, which provide support over five years, are offered to outstanding early to mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.

BiotechDispatch (4 June 2019): The new consultancy, Brandwood CKC, will provide services across pharmaceuticals and medical devices.

BiotechDispatch (30 May 2019): Regenerative medicine company Orthocell (ASX:OCC) says it has received firm commitments for a $10.6 million placement from professional and sophisticated investors, including existing shareholders.

BiotechDispatch (30 May 2019): Antisense Therapeutics (ASX:ANP) has reported that the phase 2 clinical trial of its immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD), is now fully enrolled.

BiotechDispatch (28 May 2019): Starpharma (ASX:SPL) has announced that its nanoparticle formulation, DEP irinotecan, showed significant efficacy and safety benefits over leading colorectal cancer drugs irinotecan and cetuximab in the irinotecan-refractory HT-29 human colon cancer model.

BiotechDispatch (23 May 2019): A public health program against mosquito-borne diseases and groundbreaking technology that interfaces computers to the brain, for bionic vision, are two major research projects that will progress into critical new stages of commercial development, following the announcement of federal funding today.

BiotechDispatch (23 May 2019): Medicinal cannabis company AusCann Group (ASX:AC8) has confirmed that Mr Ido Kanyon has commenced as the company's CEO.

BiotechDispatch (21 May 2019): Australian medical technology company LBT Innovations (ASX:LBT) has announced that its 50 per cent owned joint venture company, Clever Culture Systems, has received FDA approval for its APAS Independence instrument with associated urine analysis module.

BiotechDispatch (16 May 2019): The final patient has completed their last clinical visit in Opthea's (ASX:OPT) Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD).

BiotechDispatch (16 May 2019): The company has announced the appointment of Dr Paul McKenzie as its new chief operating officer.

BiotechDispatch (14 May 2019): Johnson & Johnson Innovation is collaborating with MedTech Actuator to support health technology startups in Victoria.

BiotechDispatch (9 May 2019): Shares in Australian regenerative medicine company Orthocell (ASX:OCC) soared yesterday in response to the latest news from a trial of its CelGro nerve regeneration product.

BiotechDispatch (9 May 2019):  Sydney-based Pharmaxis (ASX:PXS) has announced its US licensee Chiesi has received a positive recommendation from a committee advising the US FDA on the use of BRONCHITOL for adult cystic fibrosis patients.

BiotechDispatch (7 May 2019):  The CSIRO has announced a new $5 million partnership with GenesisCare for research into targeted new cancer treatments.

BiotechDispatch (2 May 2019): Australia’s largest life sciences investment fund administered by Brandon Capital Partners has launched a new $120 million fund.

BiotechDispatch (2 May 2019): Melbourne-based PolyNovo has been granted access to the US Department of Defence contracts through a Defence Acquisition and Program Administration and Veteran’s Affairs contract.

BiotechDispatch (2 May 2019): A new report has highlighted the changing face of drug development with new and emerging biopharmaceutical companies increasingly dominating late-stage clinical trial activity.

BiotechDispatch (30 April 2019):  Flinders University says its researchers have developed a new technique to read complex microbial populations – a technique that could also be applied to improve analysis of the human microbiome.

BiotechDispatch (23 April 2019): Brisbane-based Ellume has announced the appointment of David Green as chief financial officer and company secretary, and Mark Boyle chief business officer.

BiotechDispatch (23 April 2019): ResApp Health (ASX:RAP) has announced positive top-line results from its Australian Breathe Easy adult clinical study.

BiotechDispatch (18 April 2019): Immuron (ASX:IMC) has announced the appointment of its CEO, Dr Gary Jacob, to the Board of Directors.

BiotechDispatch (18 April 2019): Medlab Clinical (ASX:MDC) has entered into a collaborative agreement with Chronic Pain Australia regarding consumer and health practitioner medicinal cannabis education throughout Australia.

BiotechDispatch (16 April 2019): The wait is over for funded access to Novartis' CAR-T therapy with KYMRIAH (tisagenlecleucel) to be reimbursed for paediatric and young adult patients up to 25 years old with B-cell precursor acute lymphoblastic leukaemia (ALL). 

BiotechDispatch (11 April 2019): The company said the implant is designed for routine 1.5 and 3 Tesla magnetic resonance imaging scans without the need to remove the internal magnet.

BiotechDispatch (11 April 2019): Leading digital health company ResApp Health (ASX:RAP) has announced it has submitted an application to the US FDA for De Novo classification of its ResAppDx-US - a mobile software application for the diagnosis of paediatric respiratory disease using cough sounds.

BiotechDispatch (11 April 2019): Alterity Therapeutics, formerly known as Prana Biotechnology (ASX:PBT), has announced it is meeting with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow.

BiotechDispatch (11 April 2019): Factor Therapeutics (ASX:FTT), a Brisbane-based company focused on developing and commercialising advanced wound care therapies, has announced the appointment of Dr David Brookes as a non-executive director.

BiotechDispatch (9 April 2019): Seqirus has announced applications are now open for its 2019-20 ‘Championing Change’ Innovation Practice Nurse Grants.

BiotechDispatch (9 April 2019): Antisense Therapeutics (ASX:ANP) has announced that seven patients are enrolled in the nine patient Phase 2 clinical trial of its immunomodulatory therapy, ATL1102, for Duchenne Muscular Dystrophy.

BiotechDispatch (9 April 2019): CSIRO says it welcomes public discussion about the ethics of Artificial Intelligence (AI) following the release of Artificial Intelligence: Australia’s Ethics Framework.

BiotechDispatch (4 April 2019): Cynata Therapeutics (ASX: CYP) has announced that the European Patent Office has granted a patent covering its proprietary Cymerus mesenchymal stem cell technology.

BiotechDispatch (4 April 2019): The company said Malcolm McComas brings over 25 years of experience in the financial services industry with extensive experience in corporate finance, M&A, debt and equity funding transactions across multiple industry sectors.

BiotechDispatch (4 April 2019): SUDA Pharmaceuticals (ASX:SUD) has announced that the TGA has accepted for review the Marketing Authorisation Application (MAA) for ZolpiMist Oral spray for the treatment of insomnia.

BiotechDispatch (2 April 2019): Australian medical technology company LBT Innovations (ASX:LBT) has announced the commencement of its clinical study to validate the clinical performance of APAS Independence’s automatic analysis of MRSA.

BiotechDispatch (2 April 2019): Imugene (ASX:IMU) has presented new data on the Phase 1b study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta.

BiotechDispatch (28 March 2019): Australian oncology-focused biotech company Kazia Therapeutics (ASX:KZA) has confirmed it has been selected to present data from the phase 1 study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

BiotechDispatch (28 March 2019): The US FDA has received an Investigational New Drug (IND) application from Melbourne-based Race Oncology (ASX:RAC) for its cancer drug bisantrene.

BiotechDispatch (26 March 2019): Janssen, the pharmaceutical business of Johnson & Johnson, has entered a sponsored research agreement with the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University.

BiotechDispatch (26 March 2019): The federal government has announced $80 million for the development of CAR-T therapies at Melbourne's Peter MacCallum Cancer Centre and over $65 million in competitive research grants for research into personalised medicine and genomics.

BiotechDispatch (21 March 2019): Microba, an Australian company in microbiome science and testing, has partnered with Macrogen to develop new microbiome services in offshore markets.

BiotechDispatch (19 March 2019): The 2019 BridgeTech Program has officially been launched at QUT's Institute of Health and Biomedical Innovation in Brisbane.